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ABSTRACT 
 
Poor overall survival, swallowing problems and severe side-effects from multi-modality 
treatment characterize the situation of patients with oesophageal and gastro oesophageal 
junction carcinoma (GOJ). With the poor prognosis and abundance of symptoms in this 
disease it is particularly important to consider health-related quality of life (HRQoL) as an 
important outcome in clinical decision-making. Several trials have addressed outcomes 
regarding oncological therapies and surgery, though patient-reported outcomes (PRO) are 
to a large extent lacking in trials on oesophageal cancer patients.  
This thesis addresses and aims to shed light on PRO and HRQoL with a special reference to 
swallowing problems (dysphagia) during and after neoadjuvant treatment and after surgery 
in oesophageal and GOJ carcinoma. Also, an aim is to report HRQoL collected one year 
after diagnosis in a Swedish population-based register.  
 
The current main curative intent treatment regime used for oesophageal cancer is 
multimodal, including neoadjuvant oncological treatment and surgery. Due to a scarcity of 
research it is still unknown whether the addition of radiotherapy to neoadjuvant 
chemotherapy affects HRQoL and swallowing problems. In Sweden and Norway, a multi-
centre randomised controlled trial compared neoadjuvant chemotherapy (nCT) and 
neoadjuvant chemoradiotherapy (nCRT) prior to surgery, acronymed NeoRes, and PRO 
using HRQoL instruments was and endpoint in the trial. At diagnosis, the vast majority of 
the patients were in the palliative stage. Thus, adding knowledge of HRQoL outcomes in 
these settings is also very important.     
 
Paper I describes HRQoL outcomes collected in a nationwide Swedish population-based 
register twelve months after diagnosis. The outcomes were compared with a Swedish 
reference population and suggests that at one year after diagnosis of oesophageal cancer, 
subjects suffer with regard to most of the HRQoL aspects measured compared to the 
reference population, and particularly in the case of a palliative treatment intent. In 
addition, high levels of anxiety were reported in all subgroups and problems with 
swallowing were increased among those who received a palliative diagnosis and in those 
who were treated with definitive chemoradiotherapy. This study is important in order to 
increase knowledge of HRQoL outcomes in an unselected, a nation-wide population-based 
cohort.  
 
Paper II, addresses patients treated with neoadjuvant therapy, at the Karolinska University 
Hospital. These patients were assessed regarding dysphagia prior to any treatment, after the 
first cycle of chemotherapy and after completion of neoadjuvant therapy, prior to surgery. 
Patients reported dysphagia relief as already after the first cycle of chemotherapy, and after 
completed neoadjuvant therapy. This study is important for clinical decision-making at 
diagnosis of oesophageal cancer, suggesting that stents or gastrostomies may not be needed 
during neoadjuvant treatment, before surgery.  
 
Paper III addresses patient-reported dysphagia in the NeoRes trial. The data were collected 
before any treatment and after the conclusion of neoadjuvant therapy. In addition, we 
investigated whether dysphagia was correlated to histological response. This study 
confirmed the results of paper II, with an improved ability to eat solid food in both groups, 
although radiotherapy may also add side-effects that contribute to swallowing-problems. 
However, no correlation was detected between dysphagia response and histological 
response.   
Paper IV investigated the HRQoL outcome in the NeoRes trial, measured prior to 
treatment, after ended neoadjuvant treatment and one, three and five years after surgery. In 
comparisons between groups, differences were reported by patients regarding odynophagia 
after the termination of neoadjuvant therapy and coughing at three-year follow-up, both 
these symptoms was worse in patients treated with nCRT, compared to those receiving 
nCT. In addition, changes within groups in comparison with baseline were analysed. One 
finding is that regarding oesophageal-specific symptoms patients reported improvement to 
some extent. Conversely, functions and known treatment-related side-effects worsened after 
neoadjuvant therapy in both groups. In conclusion, patients reported significantly more 
severe symptoms and decreased functions after the termination of neoadjuvant treatment, 
and at three- and five-years follow-up, when radiotherapy was added.   
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1 INTRODUCTION 
1.1 ANATOMY OF THE OESOPHAGUS 
 
The oesophagus, also called the food pipe, is a part of the digestive system and it is a 
hollow, muscular tube, approximately 18-26 cm long in adults with an internal dimension 
of around 2 cm. The upper third is composed of striated muscles, while the lower two-thirds 
is composed of smooth muscle. The muscles are controlled by the cranial nerves and the 
oesophageal myenteric nerve plexus. Food passes through contraction producing 
coordinated peristaltic waves, with an inner and outer layer of muscles. The primary 
peristaltic wave is 30 mm Hg or more, and starts with the pharynx and forces the food bolus 
through the oesophagus in 6 to 10 seconds. The waves controlled by the medulla oblongata 
continue until the bolus is cleared. Two sphincters, upper and lower, permits the food to 
flow in the right direction and the lower sphincter and but mainly prevents reflux. The 
anatomical oesophagus is close to both the lungs and the heart.  
 
 
 
 
 
Figure 1. Transverse resection of human oesophagus, 
 the middle third (Sobotta)  
 
 
1.2 EPIDEMIOLOGY OF OESOPHAGEAL CANCER 
 
Oesophageal cancer is an uncommon cancer ranked as ninth in incidence but as the sixth 
leading cause of cancer deaths globally, with approximately 572, 000 new cases diagnosed 
annually and an overall mortality (509, 000 deaths), signifying that oesophageal cancer was 
responsible for 1 in 20 deaths in 2018.1  
 
Cancer is the leading cause and single most important barrier to increasing life expectancy 
globally in the 21st century. It is also the highest ranked health hazard among the 
noncommunicable diseases. Causes of cancer death vary substantially across countries and 
within each country, caused by the degree of economic growth and accompanying social 
and life style factors. It is also important to acknowledge that in many low- and middle-
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income countries, there is a lack of high-quality cancer registry data. 1 Around 80% of the 
oesophageal cancer cases occur in less developed regions 2 and at diagnoses with ages 
above 65 years. Also 70% of all cases occur in men.  1-3 
 
There are two common types of oesophageal cancer that together account for > 98% of 
oesophageal cancer cases; adenocarcinoma and squamous cell carcinoma (SCC).1,4,5 The 
most common type worldwide is SCC but this has changed in developing countries, in 
which adenocarcinoma is more common and has a rapidly rising incidence. 6  
 
Adenocarcinoma is currently the dominant histological type of oesophageal malignancy in 
North-American countries and several European countries 7 and is estimated to continue to 
rise in the upcoming decades. 8 In, Europe the highest rate of oesophageal cancer is in 
Western European countries, including the UK, Netherlands, Ireland and Belgium.9 In 
Sweden, approximately 450-500 new cases of oesophageal cancer were diagnosed  in 2016 
and it is therefore considered a rare cancer disease, in similarity with the other Nordic 
countries.10, 11 Oesophageal cancer and adenocarcinoma have been reported with a male to 
female ratio in incidence of 2.4:1 to 9:1.2,7  
 
1.2.1 Causes of cancer 
 
Causes of cancer are associated with socioeconomic development, and cancer transition is 
most striking in emerging economies, with a changing profile of common cancer types. 
Also, the Western lifestyle is described as a cause of cancer profiles.12,13 Lastly, increasing 
age and population growth reflects the risks of developing cancer.1 
1.2.2 Aetiology, risk factors and prevention of oesophageal cancer  
 
The rising prevalence of reflux and obesity worldwide are discussed as being the main 
contributors to the incidence of oesophageal and GOJ cancer.7,8  Smoking, tobacco and low 
intake of fruit and vegetables have been estimated to account for nearly 80% of carcinoma 
of the oesophagus while it has been suggested that sex hormones play a protective role.5,9 
The geographic and social group disparities of oesophageal cancer are striking with 
different etiologies.1,14 Heavy drinking and smoking and their synergetic effects are major 
risk factors for SCC in Western settings. 9 Dietary, oesophageal injury and inherited 
susceptibilities may also contribute.5  However, in low-income countries including parts of 
Asia and Sub-Saharan Africa with 90% of SCC world-wide the aetiology is currently 
unknown and the Indian Subcontinent, SCC is suspected to be caused by betel quid 
chewing. Also, in Southern American countries such as Uruguay, Brazil and Argentina, 
drinking very hot beverages especially tea is suspected to be a risk factor. Risk factors in 
Eastern and Southern Africa have yet to be elucidated.  
 
The decline in SCC incidence in the USA, Australia, France and in the UK, is believed to 
be the result of decline in cigarette smoking, while a decline in SCC in high-risk areas in 
Asia is the result of economic gains and dietary improvements.1 With the decline in SCC in 
high risk countries, the incidence of adenocarcinoma is rapidly rising, partially because of 
increased obesity and waist circumference, increasing prevalence of GERD, and 
supposedly decreasing levels of chronic infection with H. Pylori.1,7,9 Other causes that have 
been discussed as explaining gender disparities include alcohol use in squamous cell 
carcinoma and more severe reflux among men with oesophageal adenocarcinoma together 
with a protective role of high estrogenic exposure and breastfeeding among women.5 The 
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progression to adenocarcinoma is also believed to be secondary to the development of 
Barrett’s oesophagus into dysplasia and adenocarcinoma.8,9   
The prevention of cancer in the oesophagus and GOJ appear to be related to education 
about risk factors such as smoking, diet and obesity. A secondary form of prevention could 
be to treat pre-cancerous conditions, such as Barrett’s oesophagus. In addition, aspirin is 
considered to be a form of chemoprevention, with several trials ongoing.9   
1.3 PROGNOSIS 
 
Prognosis of oesophageal carcinoma is worse than for most other cancers, with an 
approximately 10–22 % five-years overall survival rate.2,7 At diagnosis, mostly of the 
patients are diagnosed at an advanced stage and therefore only offered palliative treatment.  
 
However, the main curative treatment offered is surgical resection and with evidence from 
the last decades it should preferably be employed in combination with neoadjuvant 
treatment.15,16  In patients treated with surgery, the 5-year survival rate has increased to 
40%-45%15,17,18   The CROSS trial, with randomisation between neoadjuvant 
chemoradiotherapy (nCRT) and surgery alone, reported a promising overall 5-year survival 
of 40% in all patients treated with nCRT and surgery, while patients diagnosed with SCC 
had over 60% overall and progression free survival when treated with nCRT and surgery, 
while 5-year survival after surgery alone was only 27%.15,19   
 
1.4 CLINICAL PRESENTATION AND STAGING 
 
At diagnosis dysphagia is the predominant symptom in more than 70%–90% of subjects 
and in most patients followed by weight loss.20-22 Dysphagia is considered a late alarm 
symptom because of the elasticity of the esophageal wall, and only 25% of the patients are 
considered curative when having localised symptoms at the time of presentation.23,24 
Dysphagia occurs when the tumour obstructs to 2/3 of the circumference of the lumen. 
Initially, solid food is difficult to swallow and progresses to include fluids. Difficulty in 
ingesting solids is considered to suggest a mechanical obstruction.24 Other early symptoms 
may include discomfort or occasional pain when swallowing, while absence of energy and 
strength, gastrointestinal bleeding, vomiting, indigestion, heart burn and chest pain are 
considered late symptoms.9 Late symptoms indicating advanced disease are also hoarseness 
and a severe cough.25  
 
Endoscopy is a crucial first-line investigation and an upper gastrointestinal endoscopy of 
the oesophagus and stomach enable direct visualization. It also enable a histological sample 
of tumour tissue to conclude the diagnosis.  
 
At multidisciplinary team conferences (MDT), the optimal treatment is discussed, a CT 
scan or preferably a PET-CT scan is performed and enable the detection of lymph nodes 
and distant metastases. In addition re-evaluation of the oncological treatment effect is of 
paramount importance, and usually discussed again at a second MDT. Clinical and 
pathological staging is currently determined by the TNM, 8th edition. The staging system 
classifies lesions based on the depth of the tumour invasion (T stage), the status of the loco-
regional lymph node (N stage) and the presence or absence of distant metastases (M stage) 
26   
 
Before a decision is made about therapy, patients require a physical examination and 
control of comorbidities. If necessary, an exercise stress test on a bicycle to further measure 
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physical performance level, and spirometry is used to evaluate pulmonary function. At 
diagnosis, many patients are old with comorbidities and also are found to be too unfit to be 
treated curatively. In addition, the tumour may be diagnosed with overgrowth on other 
organs or major vessels or with distant metastasis, and palliative treatment and best 
supportive care are then the options available.  
 
 
 
 
 
 
 
Figure 2. Age standardised incidence rates of oesophageal cancer both sexes and types 2018 statistics. 
Figure shows incidence areas worldwide. (Downloaded from WHO Globcan in 2019) 
 
 
 
1.5 TREATMENT 
1.5.1 Curative Treatment  
 
Currently, the predominant curative treatment option in locally advanced tumour stages 
without distant metastasis, is neoadjuvant treatment followed by radical surgery. This 
strategy has been reported in several trials to improve survival compared to surgery 
alone.15-17,27-29  When comparing between neoadjuvant chemotherapy (nCT) and 
neoadjuvant chemoradiotherapy (nCRT), the few available trials results have not hitherto 
been able to demonstrate any survival advantage of one regime over the other.18,30-32 In this 
context it may be relevant to consider that treatment with dCRT has in some controlled 
trials documented to harbor the potential to offer long term survival. Hereby, it has to be 
recognised that the selection criteria in corresponding trials are critical and often includes  
patients not suitable for surgery.33,34  The therapeutic armentarium in various stages of 
oesophageal cancer has changed significantly over the past decade with for instance the 
introduction and widespread implementation of minimal invasive surgical techniques and 
the pivotal role of endoscopic endoluminal resection for cure of early neoplastic lesions.35-38 
  5 
By the use of modern oncological treatment, centralization of the surgical treatments, less 
surgical trauma inflicted on the patients and also with the improved perioperative care, 
within fast track programmes for enhanced postoperative recovery, the entire perioperative 
courses in patients with oesophageal cancer have dramatically changed. One of the 
consequences of the therapeutic refinements has been an improved quality of life for these 
patients. To continue with such progress, more research is required that focuses on patients 
experiences and extensive evaluations when introducing new methods and programmes.39,40   
 
In order to attain a complete and comprehensive picture of the current status some 
uncertainties need to be discussed. Both surgery and oncological treatment of oesophageal 
cancer is encompassed with survival benefits, but treatment is also followed by surgery-
related complications,41 and toxicity from the treatment of oesophageal cancer is under 
reported, particularly long-term toxicity.42,43  Moreover, the structure and content of 
prehabilitation programs as well as rehabilitation programs have to be better defined and 
elucidated. Thus, the decision of the optimal treatment for each individual patient with 
oesophageal cancer is complex.22 Many important aspects of the complexity of the 
management of oesophageal cancer patients’ are reflected by a recent paper from the UK, 
applying a Delphi process, including patients, stakeholders and health professionals. The 
objective was to reach a consensus of the most important outcomes variables in trials on 
oesophageal cancer surgery. This Delphi survey was motivated by the fact that literature 
data currently available were inconsistent, lacked standard methodology and were devoid of 
core outcome. A list of 10 priorities were constructed. Top of the list was to achieve 
optimal short and long-term survival  (1–3), with minimal treatment related side-effects (4–
6), without serious nutritional problems-sequelae (7), allowing patients to eat and drink 
normally (8), avoid problems with acid indigestion (9) and, last but not least to attain a 
normal overall quality of life (10).44  
1.5.2 Surgery 
 
Oesophagectomy dates back to the late 19th century and early 20:th centuries. In 1913, a 68-
year-old woman who presented with progressive dysphagia and weight loss resulting from 
carcinoma underwent transthoracic resection which she survived for 12 years after surgery 
with a new oesophagus made from rubber.45 Different surgical techniques and 
reconstructions have thereafter been introduced and widely adopted, but the most 
commonly used surgical technique is a two stages thoraco-abdominal approach (Ivor 
Lewis), used if the tumour is located in the lower-third of the oesophagus. The three-stage 
technique (McKeown) is used, primarily in cases with the tumour is located in the upper 
third of the oesophagus. A radical and complete lymph node dissection is generally 
recommended and traditionally incorporates a two or three field lymphadenectomy.22,46  
The most common technique for reconstruction is using a gastric tube, to substitute the 
oesophagus, made out of the greater curvature of the stomach with vascular supply from the 
right gastroepiploic vessels. The ensuing oesophago-gastrostomy is done either in the chest 
or in the neck. 
 
 
Oesophagectomy is considered to be among the most demanding surgical procedures within 
the field of advanced gastrointestinal surgery. One important mechanism behind this is the 
ectensive surgical dissection required within at least two major body compartments (i.e. 
abdomen and chest). The complexity of oesophageal cancer surgery is illustrated by the 
high risk of postoperative complications. Postoperative complications within 30 days of  
surgery occur in the range of  40% to 60 % of the patients with a mortality rate of 2%–3%, 
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and in addition a recurrence rate from 32% to 54% the first postoperative year.47-50 
Mortality is also reported dependent of surgical volume.49 
 
A relatively new surgical concept is endoscopic therapy, which includes mucosal (EMR) or 
submucosal resection (ESD). This is the preferred surgical approach in early intramucosal 
carcinoma of the oesophagus (T1a) or in neoplastic lesions. These premalignant lesions are 
in the Western world most frequently diagnosed in the Barrett´s oesophagus, submitted to 
endoscopic surveillance, often connected with or preceded by high-grade dysplasia. 
Accordingly, many of these Barrett’s cases are offered radiofrequency ablative therapy 
(RFA) in order to eradicate the remained columnar lined oesophagus. Previously, treatment 
has traditionally been oesophagectomy if diagnosed with at least high grade dysplasia.36  
The tumour stage T1b is intriguing and challenging, when the absolute depth of submucosal 
invasion is critically important to assess, depending on the considerable risk of lymph node 
involvement, if the mid and deeper portions of the submucosa is involved.36  
 
The options of curative surgery are improving and a preferred surgical technique today is 
minimally invasive oesophagectomy or open-minimal invasive hybrid techniques, with 
open chest following the minimal invasive completion of the abdominal part of the 
procedure. With the introduction of minimal invasive techniques, controlled trials have 
demonstrated reduced postoperative complications, especially pulmonary complications, as 
well as a lower risk of major intraoperative complications, and shortened length of stay. 
51,52 Importantly, improved global quality of life, physical function and decreased pain as 
long as one year are reported after minimally invasive surgery compared to open surgery.53 
Robot-assisted oesophagectomy has been introduced in some centers and this technique has 
shown promising feasibility and safety but connected with higher costs. 54,55  
 
Despite the positive effects of the introduction of minimal invasive oesophagectomy, 
pulmonary complications are uniformly recognised as the most frequent postoperative 
complications and is seen in as many as 70% of the patients.49,56 In addition,  atrial 
fibrillation is common up to 20%–25% of patients both during and after the procedure to 
which can be added other serious cardiovascular complications.41,49 However, the most 
severe and life-threatening surgical complications are conduit-ischemia and anastomosis 
leakage.49,56 In this context it has to be recognised that early detection and active treatment 
of these complications have significantly improved by the centralization process and by the  
introduction of effective therapies.57,58 Other significant and clinically relevant 
complications to be aware of during perioperative care are recurrent laryngeal nerve injury 
and chylothorax. Although less comprehensive studied, late and chronic symptoms and 
complaints after oesophagectomy have yet to be elucidated. These include functional 
conduit disorders such as dumping syndrome, delayed gastric emptying, dysphagia, 
oesophageal reflux and the herniation of viscera into the chest through the widened 
diaphragmatic hiatus.49 It needs to be emphasized that complications in the perioperative 
phase not only expose the patients to a significant immediate risk but cause patients 
severely deterioration in several HRQoL domains also in the long-term perspective.59-63  
 
Prevention from serious complications is always the best strategy and the selection of 
surgical technology has already been referred to. However, the selection of patients and 
referring the patient to high volume center are of vital importance to minimize the related 
risks.9  Information is accumulating to show the importance of a number of factors during 
the prehabilitation phase of the preoperative preparation of the patients. 9 
Whether the addition of neoadjuvant chemo- or chemoradiotherapy increases the adverse 
effects of surgery remains controversial 15,17,41 but a recent metaanalysis suggested that 
nCRT was associated with more complications post-operatively. 64 Moreover, in the 
  7 
NeoRes trial, where a direct comparison was made between nCT and nCRT no significant 
differences were reported between the groups regarding the number of surgical or 
nonsurgical complications, although complications were significantly more severe among 
patients allocated to nCRT.41 
 
A pivotal role in the perioperative management of oesophagectomy patients has the 
Enhanced recovery programmes (ERP/ERAS) taken. The launch of these programmes 
seemed to have decreased morbidity, hospital stay and reducing health costs. Protocols 
optimise the care before, during and after surgery. It has further been suggested that 
increased fluid restriction with enchanced recovery programs may decrease the incidence of 
anastomotic leakage. In addition, nutritional protocols may further reduce the severity of 
anastomotic leakage. Lastly, preoperative information, early mobilisation, pain 
management and fluid control are reported to reduce pulmonary complications.57  
 
 
 
 
Used with permission by Satoshi Kamiya 
 
 
Figure 3.                Oesophagus before resection                 Oesophagus after surgery with gastric tube reconstruction 
 
 
1.5.3 Oncological treatment  
 
The main treatment in curative settings with advanced tumour stages is neoadjuvant 
treatment combined with surgery, and this has been reported in several trials to improve 
survival compared to surgery only.15-17,27-29  In comparisons between neoadjuvant treatment 
with nCT and nCRT, the results from the few trials to elucidate these modalities have not 
yet shown any significantly improved survival rates within either modality.18,30-32  In 
addition, definitive chemoradiotherapy has also been documented to have good survival 
effects. Here, the selection criteria often include that patients are not suited for surgery.33,34 
Especially patients with SCC have been shown to have good survival after dCRT. 
 
It has been clearly shown that a single agent will be enough to optimise cure of oesophageal 
cancer. Thus, a combination of two or three agents is preferred. Historically, cisplatin and 
5-Fluorouracil are the most common chemotherapy regimens, were developed in the 1970s, 
and show benefits in several other tumours.4  In the 1980s, radiotherapy was used as the 
sole form of therapy in oesophageal cancer when patients were judged not to tolerate 
surgery. However, response rates were low and when chemotherapy was added, the 
response rates and survival rate increased. Neoadjuvant treatment with cisplatin is still 
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considered the gold standard chemotherapy for oesophageal cancer, with the effect of 
downstaging the tumour, eliminating micro metastasis, thereby facilitating radical 
resection.65 Cisplatin and combined with 5-Fluorouracil is beneficial for improving five 
year survival compared to surgery alone.29  
 
The benefit of adding radiotherapy is to debulk the local tumour and decrease the number 
of lymph node metastasis, thereby increasing the chance of an operation with tumour free 
resection margins. To date, three trials, including the NeoRes trial, have compared nCT and  
nCRT, resulting in a better complete histological response by adding radiotherapy, although 
no survival benefits have been reported.18,30,32,66  Stahl et al reported a trend of improved 
survival with nCRT.30  However, in published meta-analyses, survival benefits have been 
shown in treatment with both nCT and nCRT.67,68  Newer treatments, such as the CROSS 
regime, combining carboplatin and the taxane paclitaxel with radiotherapy, have reported 
both benefits in survival, fewer complications and also HRQoL benefits.15,69-71   
 
Radiotherapy treatment is evolving with high conformal treatments including intensity-
modulated radiotherapy and volumetric modulated arc treatment. This enables oncologists 
to deliver high doses of radiation to the tumor with more precision, sparing the surrounding 
organs and tissues.65 It is currently possible to avoid surgery if a complete response, 
assessed by endoscopic and PET investigations, is achieved and this is being adopted at 
some centres that use nCRT, with the concept of “surgery as needed”.16  
 
Despite promising results in curative settings, more than 70% of  patients are at an 
advanced stage at which curative treatment is not possible and palliative treatments with 
chemotherapy, radiotherapies and stenting are widely used to palliate symptoms at 
diagnosis, together with the best supportive care.40,72-78 In selecting a palliative treatment 
regime, no benefits regarding survival has been conclusively reported, although it has been 
suggested that the  addition of oncological treatment with radiotherapy, chemotherapy or in 
combination, improve survival compared to no oncological treatment.74,76,78-81  In addition, 
palliative care is a treatment that aims to relive instead of cure the symptoms caused by 
cancer, rather than curing, thereby improving quality of life of patients and their 
relatives.40,82 Palliative care helps patients live a more comfortable life with relief from 
physical, psychosocial, spiritual and emotional problems. This is reported to be achieved in 
over 90% of advanced cancer patients supported through specialised palliative care units.40 
However, it is suggested to be a benefit if early integration of palliative care into the 
standard oncological care can be achieved, therefore an increased support within 
specialised oesophageal cancer care centres, is proposed to further improve HRQoL in 
palliative diagnosis.40,83  
 
Treatment with chemotherapy and/or radiotherapy is related to substantial toxic adverse 
effects, and it is therefore of paramount importance to systematically monitor and evaluate 
symptoms during the disease trajectory.9,84-87 In order to evaluate treatment-related side-
effects in trials in particular, since 1983, the National Cancer Institute Common Toxicity 
Criteria (CTC) system has evolved.88 The most recent version is CTCAE v5.0  (Common 
Terminology Criteria for Adverse Events). This instrument measures adverse events from 1 
to 5 (mild, moderate, severe, life-threatening and death). A report on side-effects from 
current trials are mainly based on the clinicians’ impressions of the patients’ symptoms, and 
not on patient’s own first-hand reports of their experiences with given drugs. In 
comparisons between, clinicians’ documentation and patients’ self-experienced symptoms, 
it is reported that clinicians systematically downgrade the severity of patients’ symptoms. 89  
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Platins are the oldest regime used and some side-effects are more documented than other 
chemotherapeutic agents.43  Burmeister et al compared nCRT (with platins and 5-
Fluorouracil) with surgery alone. They reported a toxic effect of nCRT, and the most 
common acute side-effects were oesophagitis, nausea and vomiting, infection, diarrhoea, 
mucositis, pneumonitis, neutropenia and increased creatinine levels.16 Another trial by 
Burmeister et al compared nCT with nCRT and they reported grade 3 toxicites. 
Neutropenia, oesophagitis, infection, renal impairment, thromboembolism and nausea and 
vomiting were reported in both groups comparing Cisplantin and 5-Fluorouracil and 35 
Gray in radiotherapy arm, no difference in grade 4 toxicity was reported in comparisons 
between groups.66  
 
In the NeoRes trial, comparing nCT and nCRT (with cisplatin and 5-Fluoruracil), no 
difference was reported regarding Serious Adverse Events (SAE) grade 3 and over, 
between groups. However, the most reported SAE were nutritional deficiency and this was 
reported in both groups, but more cardiovascular events when treated with nCRT. Other 
serious adverse events were; infection, renal failure, nausea and vomiting reported in both 
groups. Three patients died during treatment, one in nCT and two in the nCRT group. 32 
  
Newer treatments, such as CROSS treatment (oxaliplatin, taxanes and 41.4 Gray 
radiotherapy), this trial compared surgery alone with nCRT. In patients, treated with nCRT 
any grade of event is reported in the nCRT group; and anorexia, constipation, fatigue, 
nausea, vomiting, neurotoxic effects, leukopenia and thrombocytopenia were the most 
common side-effects. One patient died after conclusion of nCRT.15 
 
When adding radiotherapy, there is a risk of side-effects from the organs involved in the 
targeted dose. The oesophagus, lungs and heart are risk organs with dose-related effects and 
acute oesophagitis, dysphagia, strictures, fistulas and chronic ulcers are not uncommon 
side-effects from the oesophagus. Cardiac effects and damage with radiotherapy, is also 
increasing with dose and increases the risk factors for cardiovascular disease.90 The known 
long-term effects of radiotherapy are coronary heart disease because of the vascular damage 
and the pulmonary effects of radiotherapy are pneumonitis that manifests months after the 
conclusion of treatment and creates a risk of lung fibrosis.39  
 
1.5.4 Histological response and survival 
 
It has been reported in two meta-analysis, a strong survival benefit with both nCRT and 
nCT with surgery compared to surgery alone. Also, a larger treatment effect with increased 
complete responses, is reported with nCRT compared to nCT. However, not any survival 
benefit has thus far been reported in favor of either nCRT or nCT.31,65 The post-therapy 
pathologic stage is the most widely used and best predictor of outcome after neoadjuvant 
treatment and surgery. One of the measurements used is the Chirieac tumour regression 
scale. Using four categories the scale examines the extent of residual carcinoma in the 
specimen, called the tumour regression grade (TRG). TRG 1 means no residual carcinoma, 
TRG 2 means 1–10% residual carcinoma, TRG 3 means 11–50% residual carcinoma and 
TRG 4 means more than 50% residual carcinoma.91  
 
Like in earlier trials, the main result of the NeoRes trial was the benefit of complete 
histological response among patients treated with nCRT (28%) versus (9%) nCT.32 Despite 
a better histological response, the overall survival rate does not improve by adding 
radiotherapy.18,92 In the NeoRes trial, the overall survival rate was reported as 40% in both 
treatment groups.18
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2 HRQoL AND DYSPHAGIA 
2.1 QUALITY OF LIFE 
 
Quality of life (QoL) is a multidimensional concept with an individual’s subjective 
perception of their “position in life” and broadly evaluates both positive and negative 
aspects of life. In this setting, health and global quality of life is an important domain in the 
overall quality of life. This is subjective and with different meanings from the patients 
perspective.93 The meaning of health was broadened after World War II in 1948, and  the 
WHO included quality of life as “a state of complete physical, mental and social well-
being, and not merely the absence of disease ”. 94,95 However, the earliest reference to 
quality of life is found in the Nichomachan Ethics, by Aristoteles (384–322 BC), in which 
happiness or well-being in particular, is considered important. 
2.2 HRQoL 
 
The concept of HRQoL includes a broader meaning and includes the aspects of QoL being 
affected by disease or treatment of disease.93 Thus, HRQoL is recognised as a subjective 
measurement with a multidimensional covering of dimensions such as physical, 
psychological, occupational and social functioning.93,96  A broadly used definition of 
HRQoL is “a multidimensional construct that represents the patient’s evaluation of the 
impact of a health condition and its treatment on relevant aspects of life” and in the 
measurement of health, the definition has different meanings within the areas to which it is 
applied. 93,97,98  It is therefore important that the meaning of HRQoL is understood without 
a clearly stated definition.93 
 
The history of HRQoL research derives from randomised controlled trials, using relatively 
objective measurements to measure clinical outcomes such as cure, biological response to 
treatment and survival. Subsequently, both clinicians and patients have advocated that 
subjective measurements should also be considered, not only measuring quality of life, but 
also symptoms and treatment related side-effects.93  
 
The first modern instrument developed in clinical settings, was defined as a broad 
assessment of patients beyond physiological and clinical examinations being the Karnofsky 
Performance Status scale, and the scale was developed in 1947.99 Though considered to 
only capture one dimension of QoL, with a range from 0 to 100, where 0 is considered 
“death” and 100 “normal”  and the assessments are performed by health-care staff.  The 
next generation of instruments was developed in the late 1970s and early 1980s, with the 
quantification of a general assessment of health. The instrument focused on physical 
functioning and psychological symptoms, impact of illness and reported distress and 
satisfaction with life experienced. Examples of instruments include the Sickness Impact 
Profile (SIP) and the Nottingham Health Profile (NHP). Also, in 1976, Priestman and 
Baum, developed the linear-analogue self-assessment (LASA) method, also called the 
visual analogue scale (VAS), with a 10 cm line, describing the extremes of a condition. One 
example of LASA is the Edmonton Assessment Scale (ESAS)100,101 developed for use in 
palliative settings. It is a nine-item patient-rated symptom visual analogue scale.  
 
QoL has been discussed in the medical literature since the 1960s102, and became more 
important to health care as medical treatment extended length of life. The measurement of 
quality of life is important, because of a desire to measure outcomes beyond morbidity and 
biological functioning.39,40,97  
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An instrument currently used worldwide is the Medical Outcome Study 36-item Short Form 
Health Survey (SF-36) developed by Ware et al. in 1993. This instrument was intended to 
fill a gap between wide-ranging questionnaires and other relatively common single-item 
measures. It is designed, to provide assessment involving generic health concepts that are 
not specific to age, disease or treatment group. These generic instruments tended to cover a 
wide range of conditions and were able to compare patients against each other and against 
the population. Consequently, these instruments lacked ability to focus on issues of patients 
with a particular disease, and therefore lack the sensitivity to detect differences arising as a 
consequence of treatments especially compared within clinical trials. Today, this has led to 
disease specific instruments. Within cancer, there are three cancer-specific instruments: 
FACT-G (widely used in the US), the Rotterdam Symptom Checklist (RSCL) 103,104  and 
the European Organisation of Research and Treatment for Cancer (EORTC) QLQ-C30, 
with a broad variation between the instruments.105  In addition, disease specific modules 
can be added. For example, oesophageal cancer-specific instruments 106-108 or condition 
specific instruments have been developed as those for chemotherapy-induced peripheral 
neuropathy, cancer cachexia and patient satisfaction. 
 
2.3 PATIENT REPORTED OUTCOMES 
 
Patient-reported outcomes (PRO) is considered an umbrella term for QoL and HRQoL 
research, including a broader definition considered to be “a measurement based on any 
report of the status of patient´s health condition that comes directly from the patient (i.e., 
study subject) about the status without interpretation of the patient´s response by a clinician 
or anyone else. A PRO can be measured by self-report or by an interview when the 
interviewer only records the patients´ response”  including both measures in absolute terms 
(severity of symptom, sign or state of a disease) or as a change of a previous assessment.93  
This definition of PRO term is introduced by the Food and Drug Administration (FDA) in 
the USA and also by the European Medicines Agency (EMA). The most  widely used trial 
outcomes are survival, treatment-related survival and surrogate’s variables as treatment 
responses.109 These outcomes and adding HRQoL create a stable base from which to draw 
conclusions from trials.39 The measurement of PRO is also adopted as patient reported 
outcome measurement (PROM), it is also suggested that PRO could mean person-reported 
outcome.  
2.4 CONCEPT OF HRQOL 
 
In order to understand HRQoL, and the concept behind it and its determinants, a conceptual 
model by Wilson and Cleary is widely used. This model integrates the biological and 
psychological aspects of health and the way they affect HRQoL.110 The model has been 
revised by Ferrans and colleagues,111 and the model added the relationship between the 
individual characteristics and biological function, and thereby linking traditional clinical 
variables with HRQoL, by integrating the biological and psychological aspects of health 
outcomes.93,111,112 The model describes five different levels of patient outcomes. The first 
level is the biological function. This includes cellular and whole organ functions. 
Symptoms are the next level, and includes emotional, cognitive and physical symptoms. 
Thirdly, the functional status in the model focuses on the optimisation of patients´ 
remaining functions, and includes physical, social, physiological and cognitive functions. 
The perception of general health is a subjective evaluation, and integrates the former 
components in the model, a synthesis of all different aspects of health. The last component 
of the model is overall quality of life a subjective evaluation, integrating the former four 
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levels and generating overall quality of life. It includes the happiness and satisfaction a 
subject is with the whole life. It is considered to be a complex model, but with highlights of 
important components.111  
 
2.5 PSYCHOMETRIC PROPERTIES  
 
Depending on the purpose of the research, an instrument must be carefully selected, 
depending on what is to be measured (trial outcomes, disease, symptoms, single outcome, 
generic). It is important to consider; the timing of measurements, the frequencies of 
measurements, available resources and procedures for missing questionnaires or 
items.113,114 Furthermore, in choosing of instruments, their validity, reliability, sensitivity 
and responsiveness is  important.93 Validity considers whether the instrument measures 
what it is supposed to measures and reliability considers whether the results are random or 
reproducible. In addition, sensitivity measures whether the instruments are able to detect 
differences between patients or groups and responsiveness measures whether changes over 
time may be detected if they improve or deteriorate.93 
EORTC QLQ-C30105,115 was firstly released in 1993, for use in clinical trials because of a 
lack of common measurement of PRO. During the development, findings were that 
generally among groups of patients with more extensive or severe cancer disease they 
tended to have the lowest score on global, physical and role functions, and also scored 
highest on symptom scores on pain and fatigue scales. Also, when experiencing toxicity, 
lower scores were detected in global health/QoL, physical and role function together with 
symptoms such as nausea, pain and fatigue. It has also been  suggested that female and 
younger persons score worse.116 Several tests of psychometric properties have been 
performed to satisfy the use of QLQ-C30, both within several cancer diagnoses, stages of 
diseases and were cross-culturally tested in several countries globally.93,105,115,117-120  
 
 The instrument contains 30 questions with a four-graded Likert scale. It incorporates five 
functional scales (physical, role, cognitive, emotional, social) and three symptoms scales 
(fatigue, pain, nausea/vomiting), as well as a global health and quality of life scale, together 
with a number of single items that assess common symptoms reported by cancer patients 
(dyspnoea, loss of appetite, insomnia, constipation, diarrhoea) and the perceived financial 
impact. This is a self-administered instrument useful for making group comparisons.115  
 
To complete the general cancer instrument EORTC QLQ-C30, disease-specific modules 
have been developed. The first oesophageal instrument QLQ-OES24 was tested by Blazeby 
and co-authors in106 and was subsequently validated and updated to QLQ-OES18.107  
Additionally, an instrument for use in both oesophageal- and gastric cancer, QLQ-OG25, 
has been developed.108 The modules are designed to collect information about disease- and 
treatment–specific symptoms and side-effects. There are differences between the modules, 
but all instruments cover common scales (dysphagia, eating, reflux, pain) and single items 
covering problems such as swallowing saliva, choked, dry mouth, taste, coughing, talking. 
Also, QLQ-OES24 and QLQ-OG25 covers symptoms of anxiety and odynophagia.106,108 
 
The questionnaire items have four categories on a Likert scale: 1 not at all, 2 a little, 3 quite 
a lot and 4 very much. The global scales have a seven-step scale from “very poor” to 
“excellent”. A numeric score is usually computed according to the EORTC manual, and 
linear transection leads to a score from 0–100. A higher score on function means better 
function while a higher score on a symptom scale indicates more symptoms.115 
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Receiving a cancer diagnosis is a life-changing event and the treatment also has major 
physical, psychological and social effects and may therefore change the perceptions of 
quality of life and health. Thus, a response shift is defined as a “change in the meaning of a 
person’s evaluation of a construct as a result of a change in a person’s internal standards of 
measurement, a change in a person`s values, or redefinition of the construct”. The response 
shift masks or exaggerates a treatment effect for patient-reported outcomes such as HRQoL. 
Response shift refers to changes in internal standards (recalibration), changes of values 
(reprioritizing) and changes in meaning of quality of life (reconceptualization).67,93 Another 
way of  assessing outcomes in which a  response shift is considered is the then-test, which 
assesses both before and after at the same timepoints. Though, use of this test is considered 
to have a risk of recall bias.67 
2.6 HRQOL OUTCOMES IN OESOPHAGEAL CANCER 
 
In population-based studies it is suggested to use the general population as a comparator 
instead of using HRQoL outcomes from the diagnosis. This because patients are already 
affected by the disease at diagnosis.121 However, randomised controlled trials that compare 
treatments outcome in order to collect baseline data are very important for enabling the 
analysis of treatment effect over time and differences between groups at baseline.   
2.6.1  HRQoL outcomes with comparison of treatments in RCT’s 
 
Regarding oesophageal cancer there is a lack of trials and observational studies reporting 
HRQoL. A meta-analysis in oesophageal cancer, published in 2011, comparing oncological 
and surgical outcomes in trials, including 12 trials (1,854 patients) with randomised 
comparison of nCRT versus surgery, nine randomised comparisons of nCT versus surgery 
alone (1,981 patients) and two trials comparing nCRT with nCT (194 patients), concluded 
that a strong survival benefit of neoadjuvant treatments compared to surgery alone.31 None 
of these papers have been able to present PRO.  
 
Recently, the CROSS trial comparing nCRT with surgery alone, concluded that the overall 
survival rate was significantly higher in the nCRT group and with an acceptable treatment-
related toxicity and postoperative complication rate 15,70. The short-term HRQoL was 
recently published, and the authors concluded that no significant difference was found 
between groups at three, six, nine and twelve months after surgery with predefined 
outcomes (physical functioning, eating problems, global health/QoL, fatigue and emotional 
problems). However, in the nCRT group one week after termination of neoadjuvant 
therapy, all aspects of HRQoL were worse, but between six to nine months after surgery, 
outcomes returned to baseline levels, with the exception  of fatigue and physical function.69  
Long-term HRQoL was published in 2018, reporting data with a median follow-up time of 
105 months and reported no clinically relevant difference in HRQoL between treatment 
groups.71  
 
HRQoL outcomes comparing definitive chemoradiotherapies have though been reported. A 
French trial, PRODIGE 5/ACCORD 17, comparing FLOLFOX with a regime of 
fluorouracil/cisplatin with 50 Gray radiotherapy, they revealed no HRQoL differences 
between the treatment groups. The patients included were considered unable or unwilling to 
undergo surgery, but were curable. Data were collected, at baseline, six months, one and 
three years, and both groups experienced lower physical and social functioning, as well as a 
further increase in fatigue and dyspnoea during treatment. However, patients treated with 5-
Fluorouracil and cisplantin experienced a moderate improvement in dysphagia over time. 
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The authors concluded that it takes approximately six months until recovery to baseline 
HRQoL.122  
 
The SCOPE-1 trial also compared definitive chemoradiotherapy by adding cetuximab to 
one group. This trial closed earlier because of futility. HRQoL outcomes have been 
published, and they reported high functional outcomes at baseline, while symptoms such as 
fatigue, insomnia and eating related symptoms (appetite loss, dysphagia, dry mouth) were 
revealed at baseline. During treatment, functional aspects decreased and symptoms also 
increased, but at six months after conclusion of treatment, recovery occurred. However, 
persisting problems with severe fatigue and insomnia were reported in 15% of the patients. 
At follow up at one year and 104 weeks, the scores were similar or better than before 
treatment.123 
 
The landscape of HRQoL outcomes in trials have suffered from missing data, because 
collection of HRQoL can be administratively demanding. Thus, within several cancer 
diagnoses, many trials have been unable to present data with PRO. In trials on diseases with 
severe outcomes in particular there is a lack of publications on HRQoL outcomes.113,124  In 
areas with successful HRQoL assessments this has facilitated the shift to greater patient-
centredness in cancer care because a systematic assessment of symptoms is an important 
component of patient-centred care.40 Inadequately reporting of HRQoL may lead to a loss 
of important information or may even mislead clinical decision-making. 125   
 
2.6.2 HRQoL and neoadjuvant treatment 
 
In the CROSS trial, HRQoL was reduced in all aspects one week after termination of 
neoadjuvant treatment.69 A prospective study by Blazeby et al. compared nCT, nCRT and 
surgery alone. They reported that during neoadjuvant treatment patients reported a 
reduction in several general aspects of HRQoL; worsening of physical, role and social 
function, problems with treatment related toxicity as fatigue, nausea and vomiting, 
dyspnoea, anorexia, diarrhoea and taste where increased, although oesophageal specific 
symptoms improved or remained unchanged during nCT, although dysphagia, eating 
problems, and reflux further deteriorated during radiotherapy, but were stable or improved 
before surgery126 Similar results were obtained in a series of patients followed by Reynolds 
et al, who were treated with nCRT. Dysphagia was significantly improved but physical 
function and fatigue deteriorated significantly before surgery127 Another study found that 
nCRT had a considerable temporary effect on most aspects of HRQoL.128 
 
2.6.3 HRQoL after surgery 
 
In a nationwide Swedish population-based register with collection of data between 2001 
and 2005, HRQoL assessments have been collected and up-to-date, outcomes have been 
reported at six months and up to ten years after surgery. At six months after surgery, 
HRQoL was found to be severely impacted by surgery with a severe negative effect in 
functions, especially role and social functions and symptoms of fatigue, appetite loss, 
diarrhoea, dyspnoea and oesophageal symptoms with eating problems, coughing, reflux and 
oesophageal pain were commonly reported at six months and, at three-year follow-up after 
surgery, no improvement was detected.47,129 In addition, complications during and after 
surgery have a detrimental effect on HRQoL at six months, five years and ten years after 
surgery.59-63  However, at five-year follow up, HRQoL appears to recover to the same level 
as the background population, although in 14% of the patients who reported deterioration, 
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HRQoL was worse when compared with six months after surgery.130 Major complications 
such as respiratory failure, pneumonia, anastomotic leakage and sepsis are found to be an 
independent predictor of several parameters of poor HRQoL. Dyspnoea, fatigue and eating 
difficulties in particular were prominent at all timepoints measured ( six months, three and 
five years).61 Survivors with a presence of comorbidity at baseline, or increased co-
morbidity after surgery, reported poorer global health/QoL and worsening symptoms.131   
At ten-year follow up, HRQoL did not improve between 5 and 10 years. Instead, a decline 
in 23 out of 25 HRQoL aspects was reported and compared to an age and gender adjusted 
reference population. Ten-years survivors reported worse scores in all HRQoL aspects, with 
a significant deterioration in global health/QoL, role functioning, social functioning and 
most symptoms, the severest of which were reflux, eating problems, diarrhoea and appetite 
loss.121,132  Moreover, emotional problems are substantial after oesophageal cancer 
surgery133 and nutritional factors, such as eating difficulties and malnutrition, reduce 
HRQoL.134,135 Neoadjuvant therapy and the female gender in particular seems to be 
associated with an increased risk of malnutrition following surgery of oesophageal 
carcinoma.136 
 
In a meta-analyses, with 15 studies included, aimed at reporting HRQoL one year after 
surgery for oesophageal cancer, the findings indicated that patients will experience long-
term deterioration after surgery, particularly a deterioration in social function and an 
increase of symptoms of fatigue, pain and coughing. The paper concluded that there was a 
need for better-quality evidence for several of the HRQoL outcomes measured, especially a 
need to provide prospective nationwide cohort studies.137 
 
HRQoL measurement in oncology is considered to be on a fertile ground. Patients with 
cancer experience several symptoms and a reduction in functional ability. Many of these 
symptoms and functions are not achievable through laboratory tests or imaging procedures. 
Thus, it is necessary to rely on the patients’ self-report of symptoms.138 
  
2.6.4 HRQoL and palliative treatment 
 
Palliative treatment in oesophageal cancer is offered to prolong survival, to offer symptom 
relief, and to thereby consequently improving HRQoL124,139-141  Palliative treatments have 
not been reported with survival benefits between any treatment. Palliation of dysphagia is 
in focus in papers that report outcomes of treatments, and often, in retrospective, studies 
reporting treatment effects or side-effects.73,80,142  However, in comparisons between 
treatment with brachytherapy and stents, it is considered that HRQoL is better in the long-
term with brachytherapy while treatment with stents report better HRQoL in the short 
term143 One review comparing PRO between palliative radiotherapy and chemotherapy, 
reports a lack of HRQoL outcomes in palliative settings and highlights the importance of 
reporting PRO in this setting. With a lack of survival benefits, PRO is therefore an 
important endpoint. In addition, more intensive treatment was seen to provide better 
HRQoL, even though toxicity increased. Patients appear to tolerate side-effects to a greater 
extent when they are hopeful about the treatment effect, and in information about side-
effects may improve their coping ability. Only a few of the studies in the review reported 
clinically significant differences (4 out of 32), and the authors concluded that it is important 
to evaluate treatment effects on reported symptoms and quality of life.82    
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2.7 DYSPHAGIA 
2.7.1 Dysphagia at diagnosis  
 
Dysphagia, or “swallowing problems”, is derived from the Greek word dys, meaning bad or 
disordered, and the root phag, meaning eat. Historically, there are several references of 
dysphagia symptoms, and one early description was given by Avicenna (980-1037 AD) in 
his encyclopedia of medicine, named Canon. Although, many aspects of dysphagia remains 
to be explained. 
 
Dysphagia may be defined as either difficulty in initializing swallowing, usually described 
as oropharyngeal, or high dysphagia, or as a sensation that foods and/or liquids are 
obstructed in their passage through the mouth to the stomach (food sticks in the throat or 
chest), usually called oesophageal, or low, dysphagia. 23,144  An incidence of 33% of 
patients seeking acute health care have dysphagia, and in long-term-care facilities, 30-40% 
of patients have swallowing disturbances, mainly from neurological reasons.145,146 In 
addition, dysphagia is estimated to affect up to 50% of people over the age of 60 years of 
age.147 Consequently, it is important to distinguish between true oesophageal dysphagia 
from oropharyngeal dysphagia or other causes.148  It is also important to distinguish 
between odynophagia (pain when swallowing), and dysphagia. This may be difficult in 
oesophageal cancer though odynophagia is reported to be more transient than dysphagia 
and only persists during the 15–30 seconds that the bolus takes to traverse the 
oesophagus.149   
 
As previously mentioned, at diagnosis of oesophageal cancer dysphagia is the predominant 
symptom in more than 70%–90% of subjects and is followed by weight loss.20-22 Dysphagia 
is considered a late alarm symptom because of the elasticity of  the oesophageal wall and 
only 25% of patients are curative by having localised symptoms at the time of 
presentation.23,24 Lastly, dysphagia occurs when the tumour obstructs 2/3 of the 
circumference of the lumen. Initially, solid food is difficult to swallow and the dysphagia 
usually progresses to include fluids. Additionally, difficulty in ingestion solids is 
considered to be the result of a mechanical obstruction, such as a tumour.24   
 
Dysphagia in cancer is considered a key alarm symptom.145,150  In the UK, with a high 
incidence of adenocarcinoma, there have been awareness campaigns have been conducted 
to raise public awareness of  dysphagia and persistent heartburn, with the recommendation 
to visit a general practitioner if such symptoms are experienced.151  
 
2.7.2 Palliation of dysphagia– a bridge to surgery 
 
The main challenge in most patients with oesophageal cancer is the palliation of dysphagia. 
Experience and in-depth interviews with patients indicate that dysphagia is a troublesome 
symptom affecting all aspects of a patient`s daily life,152 and which negatively impacts 
quality of life.153   
 
Historically, dilatation has been used together with stenting to relieve swallowing problems. 
In 1885, the first intubation of malignant strictures was developed to palliate dysphagia but 
at that early time, stenting had a high incidence of rupture, fistulas and migration.154  From 
the 1960s onwards, clinicians started to systematically investigate oesophageal stents for 
dysphagia, and in recent decades, self-expanding metal stents (SEMS) have taken a strong 
position,155 especially in palliative settings, as well as during neoadjuvant treatment.155,156 A 
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stent is supported by immediate relief of dysphagia and maintenance of nutrition. A stent 
placement is usually followed by immediate relief of dysphagia. Within a couple of days 
after stent placement, the ability to eat improves.78,156,157  A number of papers, have 
investigated the role of stents as a bridge to surgery and reported safe early results with 
insertion of stents.155,157,158  On the other hand, surgeons are reluctant to consider 
preoperative stents, because of their concern about perforation, difficulties in surgical 
dissection, and future tumour resectability. Furthermore, a French retrospective survey, 
investigated 2,944 patients, and reported that stents also have a negative outcome impact on 
oncological outcomes and are a predictor of poor prognosis.159 Side-effects to be considered 
is that the employment carries a risk of perforation and may therefore jeopardize the 
planned neoadjuvant treatment159. There, is also a risk of the tumour cells spreading.160 
Peri-tumour inflammation causing fibrosis may further jeopardize the planned 
surgery.159,161 During neoadjuvant treatment with tumour-debulking effects, approximately 
32% of the stents have been reported to dislocate and chest discomfort has been reported 
with and incidence of 51%.158,162 However, newer stents with a complete silicone lining, 
enabling the stents to be removed and allowing restaging before surgery show more 
promise with respect to the above mentioned problems. Also, biodegradable stents that 
dissolve in a few months are being discussed as alternatives to SEMS. It has also been 
reported that stents containing radioactive iodine have reported better relief of dysphagia 
and survival, although these are currently only being tested in palliative settings. 76 In 
recent years, papers have reported that among patients receiving stents, an approximately 
30%-41% of the patients reports recurrent dysphagia.142,162 The European Society of 
Gastrointestinal Endoscopy (ESGE) their recently made a recommendation to avoid 
application of  SEMS as a bridge to surgery.162 
 
 
Percutaneous Endoscopic Gastrostomy (PEG) is another procedure employed to ensure 
nutrition and prevent further weight loss during neoadjuvant treatment.163  However, this is 
also considered more controversial, with a risk of damaging the future blood supply to the 
future gastric conduit, and thus contributing to anastomosis complications. In addition, a 
risk of tumor cell seeding with abdominal wall metastasis has also been reported.164 
However, it has also been reported that PEG employment does not endanger the surgical 
resection, but concerns with high adverse effect rates up to 36% and major rates of 22% at 
placements.163,165 In addition, the use of feeding jejunostomy is considered to enhance 
nutrition during neoadjuvant treatment, but it requires a transabdominal procedure under 
general anesthesia. Such a procedures also carries a risk of infection, displacement, 
obstruction or other surgical complications, with delay in starting neoadjuvant treatment166 
After surgery, a feeding jejunostomy is often used, through the postoperative phase and 
until patients have recovered and are able to cover their nutritional needs orally, with the 
support of a dietician.  
 
Nasogastric or nasojejunal feeding tubes are also proposed as a possible procedure but are 
also considered to sometimes being difficult for the patient to tolerate and have therefore 
been suggested as a short-term option, though a considerable risk of pneumonia has been 
reported with the tubes.167  Parenteral nutrition to support patients during treatment is used, 
though in the short term, taken into account evidence that suggests side-effects as 
thrombophlebitis, and sepsis infection, as well not being cost-effective.167 Lastly, 
endoscopic dilatation is used to improve swallowing. However, if the problems are caused 
by a tumour, this is not recommended because of a risk of tumour perforation.168 After 
surgery and in other benign settings, dilatation is a treatment option here.  
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All, treatments used to palliate dysphagia are considered with their pros and cons. Thus, 
each patient must be carefully selected and requirements for nutritional support must be 
individualised during neoadjuvant treatment. The consequences of dysphagia, and 
consequently weight loss are important to consider in oesophageal cancer patients because 
a substantial weight-loss is important, due to a higher risk of surgical mortality and 
morbidity.167,169   
 
Recently, a paper from the American Thoracic Society, reported in a retrospective series, 
comparing patients with or without gastrostomies. During the disease trajectory, patients 
needed expert nutritional support and it was recognised that patients with previous PEG 
placement seldom used their PEGs. The recommendation from these authors was to only 
place PEGs in a selective group of patients and instead increase nutritional support during 
treatment.163 However, it has also recently been reported in oncological settings that 
patients experience relief of dysphagia during neoadjuvant treatment, challenging the need 
for invasive procedures.170,171  
  
In HRQoL research a dysphagia scale is included in the oesophageal cancer-specific 
module and a few papers have reported that dysphagia during neoadjuvant treatment as well 
after termination of neoadjuvant therapy, dysphagia both improved and 
deteriorated.126,127,172  Firstly, during treatment with induction nCT, dysphagia is reported to 
be relieved, 126,172 Secondly, during nCRT, dysphagia was reported to worsen126 and thirdly, 
dysphagia was relieved or stabilised after termination of nCRT treatment.126,127  However, it 
is suggested that in the vast majority of studies in which dysphagia is not the primary 
endpoint, may underestimate the improvement of dysphagia.20  This is due to the inclusion 
of patients without dysphagia at baseline in the analyses, and is furthermore not considered 
if stents or other procedures to relieve dysphagia were used. This may also produce a 
source of bias in dysphagia assessment after surgery, in which interventions used to 
alleviate dysphagia, such as dilatations and stent placements, are rarely reported.123  
 
2.7.3 Dysphagia measurement considerations 
2.7.3.1 Ogilvie score173 
The most commonly used scale in clinical practice is the Ogilvie score, also called the 
Atkinson score 173 and the Mellow Pinkas score 174. In addition, this simple scoring system 
is widely used within studies and national registers and the score is also used in clinical 
practice. Dysphagia is graded on five levels (0=no problem to swallow or eat, 1=normal 
diet avoiding certain foods, 2= semi-solid diet, 3= fluids only, and 4= complete dysphagia, 
even with liquids). A newly published Swedish validation of the Ogilvie score suggests that 
the score is good to excellently reliable, with high internal consistency and stability (test-
retest reliability) with good external consistency compared to the dysphagia scale in 
EORTC QLQ-OG25. The authors suggested using the Ogilvie score in especially clinical 
practice, in particular because of its simplicity.175 
2.7.3.2 Watson dysphagia scale 176,177  
The Watson score was established to evaluate dysphagia in benign conditions. The Watson 
dysphagia score 177 combines information about difficulty in swallowing with a visual 
analogue scale independently applied to nine different types of liquids and solids, with a 
compound score from 0 to 45 ( 0= no dysphagia and 45=total dysphagia). The scale is easy 
to use and very applicable to use when interviewing patients and also very informative in 
evaluating difficulties in eating different types of food. The validation of the Watson scale 
was performed together with the Ogilvie score. The results show a good reliability and 
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reproducibility, suggesting that the Watson sale is particularly valid in clinical studies. In 
malignancy disease, patients often report intermittent or progressive swallowing problems 
and the instrument measures the frequency of difficulties.175 
2.7.3.3 EORTC QLQ-OES24106 
This instrument is the first version of an oesophageal cancer treatment module. It was 
developed in four phases: Phase I scrutinising literature within area and semi-structured 
interviews with patients and specialists, followed by a detailed interview with specialists, 
producing a list of QoL issues. Phase II constructing a provisional module with a list of items. 
Phase III pre-testing the provisional module on patients from European countries.   
 
In a test of scale reliability and an evaluation of the validity of QLQ-OES24, a new version 
QLQ-OES18107 was launched and tested prior to treatment and with a follow-up 
questionnaire in order to test the sensitivity to changes (Phase IV). Tests were performed on 
patients with oesophageal cancer with both curative options and palliative treatment 
modalities. The dysphagia scale was not changed in this new version, since the former 
version of the dysphagia scale showed an item correlation exceeding 0.40 and was reliable 
with a Cronbach’s alpha over 0.71. The QLQ-OES18 has shown moderate to good 
reliability and discriminant validity, and is regarded as a clinically and psychometrically 
valid instrument for assessing dysphagia and other items included in the instrument.  
 
In both QLQ-OES24 and QLQ-OES18, the dysphagia scale comprises three questions 
about whether patients have experienced the following symptoms or problems during the 
past week. Could you eat solid foods?  Could you eat liquidized or soft foods and, lastly 
Could you drink liquids?  It contains a four graded response alternative, 1 not at all, 2 a 
little, 3 quite a bit and 4 very much.  
 
EORTC QLQ-OG25108 This instrument has been validated to improve the assessment of 
HRQoL in both oesophageal and gastric cancer. The scale comprises three questions about 
dysphagia symptoms patients during the past week. Have you had problems eating solid 
foods? Have you had problems eating liquidized or soft foods, and lastly, Have you had 
problems drinking liquids? 
The aim of the new instrument was to combine the existing oesophageal module with the 
gastric cancer module QLQ-STO22, and include a proposed new three-item dysphagia 
scale, among other scales. The items were already included in both scales but with different 
wording. During the completion, a semi-structured interview investigated patients’ opinions 
and preferences for the items and scale. Patients were asked about which dysphagia scales 
they would keep in the new questionnaire and why they selected this option. In addition, 
observer records were also kept. The preferred dysphagia scale was the one used in QLQ-
STO22, because being ease of understanding. Also, observers noted that patients completed 
this scale correctly. Multi-trait scaling analyses, reliability and validity tests indicates that 
the new instrument is reliable and valid.108 
 
2.7.4 Consequences of oesophageal dysphagia and treatment 
 
There are major nutritional consequences to be considered for patients as weight-loss 
followed by malnutrition and sarcopenia are common. Malnutrition is reported in over 60 
% of diagnosed oesophageal cancer patients and thereby one of the highest frequencies 
within oncologic conditions.167,169  Malnutrition in oesophageal cancer often combines low 
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intake due eating disability with cachexia, which is often combined with anorexia.178 In 
addition, malnutrition may be caused by increased catabolism, because of infections or 
surgical intervention.135,178,179  Dysphagia causes a seriously risk of cough by aspiration and 
pneumonia.7,23,167 Patients at diagnosis with both dysphagia and a greater weight loss 
greater than 15%, and often also a low plasma albumin concentration, tend to be 
malnourished and often have disseminated disease at diagnosis.169  During treatment 
trajectory it is necessary to continuously screen, assess and follow-up dysphagia, weight 
loss and other symptoms that cause negative quality of life.9,167,171  
 
Dysphagia is the main symptom at diagnosis and if the patients experiences that swallowing 
problems recur after initial treatment, anxiety is common, mainly because of fear of 
recurrence. 133  However, benign causes such as strictures that require dilatations are also 
not uncommon. “Normal” gastrointestinal function is reported in lower than 20% of 
patients following oesophagectomy. Functional conduit disorders cause poor digestive 
function, and this includes dumping syndrome, delayed gastric emptying, dysphagia and 
reflux.23 Dysphagia is also reported in up to 65% of patients after oesophagectomy 23,180 
 
In one study palliative patients’ experience of dysphagia was investigated through 
interviews and subsequently patients completed a HRQoL questionnaire. The authors 
reported that five themes emerged, namely, recognizing dysphagia, the physical experience, 
the emotions evoked, the impact on social life and dysphagia and treatment. The patients 
included were only able to eat semi-solid food.152 Patients reported that at diagnosis they 
never considered cancer as a cause of their dysphagia, and there was therefore a delay in 
receiving a diagnosis. In addition, the long time taken to finish a meal and the pain and 
choking symptoms were a cause for concern. They also experienced problems relating to 
mucus and phlegm. Weight loss and the emotional feelings evoked by dysphagia involved 
feelings of fear, insecurity and anxiety about eating. The impact on their social life was 
affected and they expressed severe concerns. Also, they were reluctant to eat in front of 
others, including close family members, because of embarrassment caused by the 
dysphagia. The main findings were that dysphagia is distressing  and impacts the patients 
physical, emotional and social well-being.152  
 
Several papers, included in four previous theses from Sweden have highlighted the need for 
support for patients and their relatives when they are diagnosed with oesophageal cancer, 
including support by subspecialized nurses working in multidisciplinary teams. 
85,86,133,153,181-186 Andreassen et al, have focused on patients and family members need of 
information,181-183 dysphagia, fatigue and uncertainty influenced patients everyday life, and 
information seeking was one strategy to manage illness.182 Viklund et al. investigated the 
complex care pathway and reported that patients experienced a need of supportive care 
given by a specialist nurse and especially the need of nutritional support was dominated.184  
In addition, a well-organised and nurse led care pathway were found to be well-working 
and an appreciated model.85 Malmstrom et al, have illuminated patients experiences of 
supportive care after oesophageal cancer surgery. The findings were that patients needed 
comprehensive supportive care after surgery and especially a need to develop a plan for the 
future including honest and realistic patient information of how to cope their new life-
situation.86 In addition, a proactive nurse-led telephone follow-up has a significant positive 
impact on the patient’s ability to cope with a life with remaining side-effects from 
treatment.185,186 Also, the European recommendation for the future care for oesophageal 
cancer patients urges the need of specialised multidisciplinary teams in order to improve 
HRQoL and survivorship.9  
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2.7.5 Histological response versus dysphagia relief 
 
Because of dysphagia response during neoadjuvant therapy, many studies have addressed 
the question of whether clinical response of dysphagia is correlated to histological tumour 
response. Hitherto, the published studies that investigated this research question within 
different time-frames after or during neoadjuvant therapy, have not been able to detect any 
correlation between dysphagia response and histological tumour response. 172,187 
 
a   b 
  
 
 
Fig. 4  FDG-PET/CT of a 72 years old male patient with T3N0M0 squamos cell carcinoma of middle  
oesophagus at diagnosis, before neoadjuvant chemo-radiotherapy.  Black arrows is site of tumour FDG uptake.  
 Figure. 4b  FDG-PET/CT images in unfused and fused states of the same patient as in figure 
, at follow-up examination four weeks following completion of neoadjuvant chemoradiotherapy.  
No remaining pathological uptake discovered in the tumour. 
 
Courtesy dr Stefan Gabrielsson 
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3 AIMS 
 
The overarching aims of this thesis is to increase the knowledge about HRQoL and 
swallowing problems in subjects diagnosed with oesophageal cancer. 
 
The aim of paper I is to describe and analyse HRQoL one year after the diagnosis of 
oesophageal and GOJ carcinoma in an unselected nation-wide population-based cohort 
comprising both palliative and curative intent patients 
 
The main aim of paper II is to prospectively assess changes in dysphagia during and after 
neoadjuvant therapy in a cohort of consecutive patients with oesophageal or GOJ 
carcinoma. 
 
The main aim of paper III is to compare the effects on dysphagia of nCT and nCRT, and 
further to study the association between dysphagia response and histological tumour 
response to neoadjuvant therapy. 
 
The main aim of paper IV is to study short- and long-term HRQoL among patients 
randomised in the NeoRes trial, comparing patients allocated to either nCT or nCRT. 
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Table 1.   Overview of materials and methods for papers I-IV 
 
 
 
 Paper I Paper II Paper III Paper IV 
Design Population 
based cohort 
Prospective 
cohort 
Randomised 
controlled trial 
Randomised 
controlled trial 
Data source NREV, Sweden Karolinska 
University 
Hospital  
Multicentre, 
Sweden and 
Norway 
Multicentre, 
Sweden and 
Norway 
Data Collection 2009–2016 2011–2013 2006–2013 2006–2018 
Study time One year after 
diagnosis 
Before any 
treatment, after 
first chemotherapy 
cycle and before 
surgery 
Before allocated 
treatment and after 
neoadjuvant 
treatment but 
before surgery 
Before allocated 
treatment, after 
ended neoadjuvant 
treatment but 
before surgery, 1, 
3 and 5 years after 
surgery 
Outcome HRQoL Dysphagia, 
appetite, weight 
and histological 
response 
Dysphagia, weight 
and histological 
response 
HRQoL 
Patients included 1156 35 156 165 
Male gender % 82% 91% 82% 82% 
Age median (range) 68 (29–93) - 63 (39–75) 63 (37–75) 
Adenocarcinoma % 69% 83% 73% 73% 
Statistical 
analysis 
Mean, MD, 
adjusted linear 
regression 
ANOVA Mann Whitney U 
test, linear 
regression, 
Wilcoxon rank 
sum, Chi-square  
Mean, MD, linear 
mixed effects 
models with time 
interaction and 
linear regression 
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4 SUBJECTS AND METHODS 
4.1 THE NEORES TRIAL 
 
Papers II, III and IV are reports from the NeoRes (Neoadjuvant therapy for Resectable 
Esophageal Cancer) trial. The trial was conducted within the Scandinavian Esophageal and 
Gastric Cancer Group (SEGCG), enrolling the first patient, in the third quarter of 2006 and 
the last patient in the first quarter of 2013. A final five-year follow-up ended in June 2018. 
The trial is registered at ClinicalTrials.gov: NCT01362127 and the trial was not funded by 
any commercially support. 
4.1.1 Study cohort 
In the NeoRes trial, centres in Sweden and Norway included patients and the sponsor of the 
trial was Karolinska University Hospital. In Sweden, four specialised surgical/oncological 
centres included patients (Stockholm, Umeå, Örebro and Göteborg), while in Sweden 
oncological treatment was also given at Mälarsjukhuset in Eskilstuna and Karlstad County 
Hospital. In Norway, three specialised centres included patients: St. Olavs Hospital in 
Trondheim, University Hospital in Oslo and Haukeland University Hospital in Bergen.  
4.1.2 Eligibility criteria 
Patients with histologically confirmed adenocarcinoma or squamous cell carcinoma of the 
oesophagus or GOJ (gastric cardia type I and II) were eligible for resection and oncological 
treatment was offered at inclusion. The disease stage at inclusion (T1N1 or T2-3N0-1 and 
M0-M1a) were defined according to the American Joint Committee on Cancer tumor-
nodes-metastasis staging system 6th edition. Patients with cervical cancers were required to 
be resectable without laryngectomy. Patients with aged at 75 years or less with a 
performance status of 0–1 according to the WHO scale, and with resectable primary 
tumour, were assessed at the pre-randomisation evaluation. Blood samples were collected 
and values within normal limits of hematological and renal function were also required. 
The patients were not allowed to have any condtion that would render chemoradiotherapy 
unsuitable, as well as a life expectancy of at least three months. Written informed consent 
was given and signed by the patients.  
4.1.3 Pre-treatment evaluation 
Patients were diagnosed with an upper gastrointestinal endoscopy and Computed 
Tomography (CT) of the upper abdomen and chest. After a protocol amendment, the use of  
Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET/CT) and endoscopic 
ultrasonography were recommended. Before treatment, evaluation of respiratory and 
cardiac functions tests were to be performed as well as an audiometry test, before 
oncological treatment.  
4.1.4 Study design and statistical analysis 
The trial is a prospective open phase II multicentre randomised clinical trial. The study 
population comprised patients diagnosed with adenocarcinoma or squamous cell carcinoma 
of the oesophagus or GOJ. The primary endpoint was histological complete primary tumour 
response (ypCR) after resection. Sample size calculation was performed to meet criteria of 
the primary endpoint, and resulted in 172 patients in order to meet criteria of 80 % power 
was calculated. To ensure meeting the primary outcome, 180 patients were to be included. 
The main analysis was performed on intention to treat basis. 
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All study data were collected and stored at Karolinska University Hospital and at each 
participating centre in accordance to applicable laws and reserach ethics. A web-based 
database was accessible to the investigators.  
4.1.5 Randomisation 
All patients were randomised at the Regional Cancer Centre in Stockholm, usually via fax 
and/or a telephone. Patients were stratified by histology, and a computer programme with 
block permutation was used at the randomisation. The allocation sequence was concealed 
from all investigators. 
4.1.6 Ethics 
The trial was performed in accordance with the Helsinki Declaration (as amended by 
Tokyo, Venice and Hong-Kong), and with the laws and regulations within the countries, 
that affords the greater protection of the individuals. The trial was registered in EUDRACT 
and accepted by the Swedish Medical Agency with ethical approval in both Sweden and 
Norway. The Swedish Research Ethics Committee in Stockholm, registration number 
2006/738-32 and 2008-403-32, and in Norway: Central Norway Regional Health Authority 
with registration number 4.2008.416. The trial is registered in the Clinical Trials Database 
(https://clinicaltrials.gov; registration number NCT01362127).   
4.1.7 Chemotherapy 
Neoadjuvant treatment was started within two weeks of randomisation and three cycles, 
given at one, four and seven weeks of treatment with cisplatin (100 mg/m2 day one) and 5- 
Fluorouracil (750 mg/m2 at days one to five). Amendments were accepted during the trial. 
If patients were detected to have a hearing impairment, tinnitus or deterioration of renal 
functions Cisplatin was replaced by Carboplatin and Oxaliplatin in patients with 
adenocarcinoma and AUC 5 in patients with squamous cell carcinoma.  
4.1.8 Chemoradiotherapy 
Patients allocated to chemoradiotherapy received 40 Gray radiotherapy together with the 
same chemotherapy regimen as those allocated to chemotherapy alone. Radiotherapy 
started together with chemotherapy cycle number two, with 2 Gray daily, five days per 
week, over four weeks, using a photon beam linear accelerator. A three-dimensional dose 
planning system was used. To minimise doses to other organs, doses to the lungs exceeding 
20 Gray were kept as low as possible and did not exceed one third of the lung. Volume to 
the hearts was kept at a minimum when the doses exceeded 30 Gray. Doses to both the 
kidneys were to be kept to a low volume and not exceed 12 Gray and to one kidney not to 
exceed 20 Gray. Maximum dose to the spinal cord was 40 Gray.  
Patients were positioned and immobilised in a supine position with their heads on a 
standard headrest and preferably the arms above the head, in order to permit a multiple field 
technique. Patients with lower lung function were given a special attention to avoid 
radiation-induced pneumonitis and subsequent radiation fibrosis. 
 
 
4.1.9 Surgery 
The surgery was scheduled four to six weeks after completion of the allocated neoadjuvant 
treatments. In order to minimise morbidity and mortality, only centres with documented 
experience of cancer surgery of the oesophagus or GOJ and the stated procedure in protocol 
were allowed to participate. The operations were planned with a thoraco-abdominal 
resection with an intrathoracic anastomosis (Ivor Lewis procedure) for cancers in the distal 
third and cardia whereas a three-stage resection (Mc-Keown procedure) was carried out for 
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patients with tumours in the middle and upper part of the organ. If the individual surgeon 
considered it appropriate, other procedures were permitted. Other procedures included 
transhiatal esophagectomy, only employing laparotomy and a cervical incision for distal 
oesophageal and junctional cancers. Total gastrectomies were permitted for junctional 
tumours classified as Siewert II.   
4.1.10 Assessments during treatment 
Before any treatment, the patients’ symptom were reviewed and assessed accordingly with 
blood samples, nutritional assessments and the use of the US National Cancer Institute`s 
Common Terminology Criteria for Adverse Events (NCI CTCAE v. 3.0), which was scale 
modified to this protocol. During neoadjuvant treatment, patients were assessed at least 
every third week and weekly during radiotherapy. Serious adverse forms (SAE) were 
reported to Stockholm Regional Cancer Centre and to the principal investigator in 
accordance with good clinical practice (GCP).  
4.1.11 Follow-up 
Follow-up visits after surgery were planned every third months during the first two years, 
and then every sixth months until five years after the end of treatment.   
4.1.12 Health-related quality of life 
Measurement of patient reported outcomes the EORTC their general HRQoL 
questionnaires QLQ-C30 and disease-specific modules were used. Assessments were 
performed before neoadjuvant treatment after completion of neoadjuvant therapy and at 
annual intervals during the follow-up after surgery, up to five years.  
4.2 PAPER I 
4.2.1 Study design 
A cohort study population was registered from 1 January 2009 to 31 December 2016. The 
data used comprised prospectively collected exposure and outcome retrieved from the 
Swedish National Register for Esophageal- and Gastric Cancer (NREV). All patients alive 
one year after diagnosis and registered in the NREV completed patient-reported outcomes 
using the European Organisation of Research and Treatment their cancer general 
questionnaire QLQ-C30 and the oesophageal disease specific module QLQ-OG25 to 
describe health-related quality of life outcomes in patients diagnosed with both curative and 
palliative treatment of care. Known confounders (age, gender, histology) were adjusted for 
in the HRQoL analysis.  
4.2.2 The Swedish National Register for Esophageal and Gastric Cancer 
(NREV) 
The nationwide register was started in 2006, and up to today 95% of patients diagnosed 
with oesophageal cancer are registered. A validation study performed on the register, 
reported that 94% of the data registered are accurate.188 Data is centrally monitored at the 
six Regional Cancer Centres in Sweden and all patients at diagnosis are required to be 
registered in the database. Responsibility for collecting PROMs was managed by the 
regional cancer centres from 2006 to May 2015. From May 2015 they are collected 
nationwide from the Regional Cancer Centre in Umeå.  
4.2.3 Exposure 
At diagnosis, the patients are registered in the register as either palliative or curative, and 
the intended treatment is also registered. This is usually decided at multi-disciplinary team 
conferences (MDT). In addition, patients were divided according to disease severity. 
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Patients with curatively intended treatment and who completed questionnaires are sub-
classed according to T-stages (T0–T1 versus T2–T4) at diagnosis and treatment is 
determined with either surgery or definitive chemoradiotherapy in the curative cohort. In 
addition, the palliative cohort is classified according to metastasis (M1 disease), advanced 
tumour stage T4 (included both T4a and T4b) and other reasons, mainly comprising the low 
possibility of tolerating demanding palliative therapy. All included patients are categorised 
according to the above criteria’s and included if alive one year after diagnosis. 
4.2.4 Definitions of outcomes 
The primary outcome of the study was HRQoL one year after cancer diagnosis comparing 
between palliative and curatively intended treatment and sub-groups. In addition, a 
comparison cohort of 4,910 Swedish age- and gender adjusted general population for 
collected in 2008 was used.  
 
Data were sent by mail to all patients registered and alive one year after diagnosis. All 
reported items from the EORTC HRQoL both QLQ-C30 and QLQ-OG25 questionnaires 
were included in the analysis. The core questionnaire QLQ-C30 contains nine multi-item 
scales measuring global health/quality of life and functions (physical, role, emotional, 
cognitive and social) and multi-item symptom scales (fatigue, nausea and vomiting, and 
pain), and six single items measuring general cancer symptoms (dyspnoea, insomnia, loss 
of appetite, constipation, diarrhoea and financial problems).115 The disease specific 
oesophageal module instrument (QLQ-OG25) contains one function scale measuring body 
image, six multi-item symptom scales (dysphagia, eating, reflux, odynophagia, pain, 
discomfort and anxiety) and nine single-item scales (eating with others, dry mouth, trouble 
with taste, trouble swallowing saliva, choked when swallowing, trouble with coughing, 
weight loss and hair loss).108 However, the item hair loss was only answered if experienced.  
All items have a 4-point Likert scale from (1) “not at all”, (2) “a little”, (3) “quite a bit”, 
and (4) “very much”, with the exception of the global health/quality of life scale with a 
seven-point scale ranging from (1) “very poor” to (7) “excellent”.  
4.2.5 Statistical Analysis 
HRQoL outcomes were described with mean and 95% confidence intervals. Adjusted mean 
differences were reported and statistically significance was tested only if relevant clinical 
significance was obtained with pre-defined mean differences. To aid the interpretation of 
differences, within the general cancer module EORTC QLQ-C30 we adapted clinical 
significance according to Cocks et al.189 This was interpreted in all items with the exception 
of emotional function. We considered the emotional function and the oesophageal module 
QLQ-OG25 clinically worthwhile here in accordance with Osoba et al. 190 and King.116 The 
statistical significance test was only performed if clinical significance was obtained. The 
analysis was performed using linear regression with adjustment for age as continuous data, 
gender as binary categorical data, histology as multilevel categorical data and also T stage 
in the curative cohort from T2–T4 as well as for definitive chemoradiotherapy. 
4.2.6 Ethics  
Ethical permission was granted by the Regional Research Ethics Committee in Sweden and 
with amendments (Dnr: 2013/596-31/3 and 2016/1486-32). 
4.3 PAPER II 
4.3.1 Study design 
A cohort study performed at Karolinska University Hospital, included patients diagnosed 
with oesophageal cancer and GOJ after discussion at multidisciplinary team conferences 
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(MDT). Patients were screened for inclusion and included from February 2011 and to 
September 2013.  Inclusion criteria comprised patients with resectable carcinoma of the 
oesophagus or GOJ considered to tolerate both neoadjuvant treatment and surgery. Patients 
with neoadjuvant treatment outside Karolinska University Hospital were excluded. 
Treatment given was mainly cisplatin and 5-Fluorouracil during weeks 1, 4 and 7 in the 
neoadjuvant setting, while in patients who also received radiotherapy the treatment started 
at cycle two, week 4.  
4.3.2 Outcomes 
Main outcome was to prospectively assess dysphagia and appetite before neoadjuvant 
therapy, after first cycle and after completion of neoadjuvant therapy. Secondarily, we 
assessed whether dysphagia response was associated with the presence of histological 
response. 
 
The assessment of dysphagia was performed by the main author (BS) and (JE), called the 
secondary other in the paper. The assessment was performed during clinical visits or by 
telephone at baseline, after the first cycle of chemotherapy and after completion of 
neoadjuvant therapy before surgery.  
 
To assess dysphagia, two instruments were used: Ogilvie score, which is a five-graded 
score and divides dysphagia into five levels where 0 equals no dysphagia, 1 is defined as 
eating normal diet but avoiding certain foods such as raw apples and meat, 2 is defined as 
intake of semisolid diet, 3 is defined as tolerating intake of fluids only, while 4 is defined as 
complete dysphagia, even for fluids. This instrument is used at our department to evaluate 
dysphagia.173 
 
The Watson scale is mainly designed to evaluate benign diseases of the oesophagus, but is 
also used within studies of oesophageal carcinoma. The Watson scale uses a visual 
analogue scale that describes nine different types of solids and liquids using three response 
alternatives for each, to produce a composite score. With 0 corresponding to no dysphagia 
and 45 as total dysphagia.176,177 
 
The ESAS-VAS appetite (Edmonton Symptom Assessment Scale) score that is mainly used 
in palliative settings was used to assess appetite. It contains a ten-graded visual analogue 
scale where 0 is absent symptom, meaning a good appetite and 10 worse possible, meaning 
no appetite.100 
 
Histological primary tumour response, the tumour regression grade was assessed by 
Chirieac 91 a modification of the Mandard scoring system. Complete histological response 
is defined as no remaining tumour (A), B < 10% of the tumour cells viable, C 11-50% of 
the tumour cells viable, and D, defined as non-responders, with > 50% of the tumour cells 
are viable and remaining in the specimen.  
4.3.3 Statistical analysis 
Analysis of outcomes were measured at three time-points and a general linear model 
repeated measure (ANOVA) was performed to examine the treatment effect on dysphagia, 
appetite and weight changes. To examine correlation between the improvement in 
dysphagia and histological response of neoadjuvant therapy, also repeated measure 
ANOVA was used. 
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4.3.4 Ethics  
All patients signed a written informed consent form. The study protocol was approved by 
the local ethics committee (Dnr: 2006/738-32, 2008/403-32, 2013/ 708-31/1) 
4.4 PAPER III  
4.4.1 Study design 
Patient-reported dysphagia using PRO in a randomised controlled trial with the acronym 
NeoRes. The EORTC oesophageal cancer-specific modules were used to describe 
dysphagia before and after neoadjuvant treatment. In addition, we explored whether there 
was any relationship between dysphagia relief and histological tumour regression in the 
NeoRes trial.  
4.4.2 Definition of outcomes 
Dysphagia was assessed using patient-reported outcomes collected in the trial. Dysphagia 
was reported in the EORTC disease-specific instruments and three items assessing 
problems or ability to eat solid, semisolid or only liquids were used. The items have a four-
graded response grade from 1, no problem, 2 to little problem, 3 quite a bit to 4 very much 
problem.  
Patho-histological response The Chireac tumour regression grade was assessed as 
described in Paper II. However, all specimens in the NeoRes trial were examined by a 
group of expert pathologists at Karolinska University Hospital in Stockholm being blinded 
to the treatment allocation.   
4.4.3 Statistical analysis 
Data were transformed according to the EORTC manual191 and also missing data were alos 
analysed according to the manual. Data are presented as mean with a 95 % confidence 
interval. A mean difference of at least 10 in mean scores was considered clinically 
relevant.190 Data analysis regarding dysphagia outcomes, both the Mann-Whitney U-test 
and a linear regression, were used in two different settings. To compare outcomes with 
dysphagia relief and histological outcome, a chi-square test was used or, if appropriate 
Fischer’s exact test. Multivariate regression (adjusted for possible confounders such as age, 
gender histology and T stage) was performed to assess whether relief of dysphagia was 
associated with histological response. 
4.4.4 Ethics 
The NeoRes trial was approved by the research ethics committees in Sweden and Norway. 
The trials were registered in EUDRACT and accepted by the Swedish Medical Agency.. 
The Swedish Research Ethics Committee in Stockholm, registration number 2006/738-32 
and 2008/403-32, and in Norway; Central Norway Regional Health Authority with 
registration number 4.2008.416. The trial is registered in Clinical Trials Database 
(https://clinicaltrials.gov; registration number NCT01362127).   
 
 
4.5 PAPER IV 
4.5.1 Study design 
Health-related quality of life assessments in the NeoRes Trial. Patients completed validated 
and tested EORTC HRQoL instruments at baseline before any treatment, after conclusion 
of neoadjuvant treatment and at one, three- and five-years follow-up after surgery.  
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4.5.2 Definition of outcomes 
The European Organisation for Research and Treatment of Cancer (EORTC), the general 
cancer instrument QLQ-C30 and the oesophageal disease module QLQ-OES24/OG-25 with 
report of differences between treatment groups and also changes over time within groups.  
4.5.3 Statistical analysis 
Data were linearly transcribed according to the manual and missing data were reported 
according to recommendations. Over one half of the items need to be included in a scale. 
Data were reported with mean and mean differences and statistically tested with a linear 
mixed effect model with time interaction and linear regression. Graphs and group 
comparisons were analysed using panel data, allowing all subjects to be included. The 
presentation of data was according to intention to treat and unadjusted analysis. To reduce 
the risk of multiple-testing spurious results, only data with mean differences over or at least 
ten in accordance with a normally used standard were statistically tested and presented with 
mean differences and a 95% confidence interval with statistical significance assumed with a 
p-value <0.05.   
4.5.4 Ethics 
Signed informed consent was obtained from all subjects. The trials were registered in 
EUDRACT and accepted by the Swedish Medical Agency, as well as ethical approved and 
in both Sweden and Norway. The Swedish Research Ethics Committee in Stockholm, 
registration number 2006/738-32 and 2008-403-32, and in Norway: Central Norway 
Regional Health Authority with registration number 4.2008.416. The trial is registered in 
the Clinical Trials Database (https://clinicaltrials.gov; registration number NCT01362127).   
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5 RESULTS 
5.1 PAPER I 
During the study period between 2009 and to the end of 2017, 1,156 subjects responded to 
the questionnaires and were accessible for inclusion. In total 2,292 subjects were alive one 
year after diagnosis of oesophageal or GOJ carcinoma and were reported in the nation-wide  
Swedish registry for carcinoma in the oesophagus (NREV) (Figure 5). 
 
Characteristics of the included subjects are presented in Table 2. In general, subjects were 
mainly diagnosed with adenocarcinoma with location in the distal oesophagus and 
diagnosed with a tumour stage T2–T3. The highest frequency of WHO performance status 
is 0–1 and ASA comorbidity grade 1–2, though in the palliative cohort more subjects were 
reported with worse WHO performance status and ASA comorbidity grade. The groups 
were found balanced between responders and none responders. In total HRQoL formulas 
were completed by more than 55% of the curative patients while only 40% of those treated 
with palliative management intention (Table 2, Figure 5). 
 
Description of the reference population and the cohort of subjects with oesophageal cancer 
The majority of the subjects included in this study reported lower mean levels in functions 
and a higher degree of symptoms compared to a Swedish reference population in almost all 
items and scales reported within the QLQ-C30 instrument. Regarding function scales, 
cognitive function was lower in both the curative and palliative cohort, but the other 
included function scales were even lower (physical, role, emotional and social). Among 
symptom scores, all scores reported are higher in subjects with oesophageal cancer one year 
after diagnosis compared to the reference population (Table 3). 
 
HRQoL comparisons between the curative and the palliative intent cohort 
In analysis, between the curative and the palliative cohort, lower physical function was 
reported among subjects with palliative intent treatment (MD -11, 95 % ci: -14 to -7). 
However, subjects with curative intended treatment reported a more problems with 
diarrhoea (MD -9, 95% ci: -13 to -5) compared to the palliative cohort. Analyses of the 
oesophageal-specific module, dysphagia (MD 11, 95% ci: 7 to 15), anxiety of future health 
(MD 10, 95% ci: 6 to 15), eating with others (MD 12, 95% ci 8 to 17) and trouble with taste 
(MD 10, 95% ci 6 to 15) were reported with more problems among subjects receiving 
palliative intent treatment. All differences reported were both clinically relevant and 
statistically significant (Table 3).  
 
 
HRQoL subgroup comparison within the curative intent cohort 
Firstly, comparing early tumours (T0–T1) and advanced tumors (T2–T2), fewer problems 
with eating (MD 10, 95% ci 5 to 15) and weight loss (MD 18, 95% ci 11 to 25) were 
reported if early tumour diagnosis. All differences reported were both clinically relevant 
and statistically significant (Table 4). 
 
Secondly, in comparisons between subjects with early tumour stage and dCRT. Subjects 
with early tumour stage reported more problem with diarrhoea (MD -10, 95% ci -17 to -3). 
However, more problems were reported regarding dysphagia (MD 16, 95% ci 8 to 25), 
choking when swallowing (MD 13, 95% ci 5 to 20) and talking (MD 13, 95% ci 6 to 20) in 
subjects treated with dCRT. All differences reported were both clinically relevant and 
statistically significant (Table 4). 
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Lastly, in comparisons between advanced tumours (T2–T4) and dCRT cohorts, more 
problems with diarrhoea was reported in the advanced surgery cohort (MD -14, 95% ci -20 
to -8) compared to dCRT. In addition, dysphagia (MD 11, 95% ci 4 to 18) and choking 
(MD 10, 95% ci 4 to 16) were reported with more problems in subjects treated with dCRT. 
The differences reported were both clinically relevant and statistically significant (Table 4). 
 
HRQoL sub-group comparison within the palliative intent cohort 
All subjects diagnosed in the palliative stage were sub-grouped.  Firstly, those diagnosed 
with metastasis (M1), secondly advanced tumour stage (T4) and lastly others (mainly 
fragile subjects with comorbidities or who did not want treatment). Only a few clinically 
relevant differences were reported in comparisons between groups. Subjects diagnosed with 
metastasis reported more problem with dry mouth (MD -24, 95% ci -45 to -4) compared to 
subjects with advanced tumour stage. More problems relating to hair loss were reported in 
subjects diagnosed with metastasis (MD -13, 95% ci -26 to 0) compared to advanced 
disease stage. Lastly, more problem with dysphagia is reported in subjects diagnosed with 
advanced locally tumour (MD -18, 95% ci -33 to -3) compared to subjects diagnosed with 
other reason. All differences reported were both clinically relevant and statistically 
significant (Table 5). 
 
 
 
 
 
Figure 5.  Flow-chart of the included patients who completed European Organisation for Research and 
Treatment of Cancer the general questionnaire QLQ-C30 and the oesophageal module QLQ-OG25  
 
 
Swedish National Register for 
esophageal and gastric cancer 
Assessed for eligibility (N =14675)
Assessed for eligebility 
n=7827
Excluded patients 
diagnosed with gastric
Cancer, ICD diagnosis C16.0C,
C16.1-9 and D00.2        n=6848
Excluded patients not alive 12 months 
after diagnosis                       n=4431
Excluded patients included between 
2006-2008, 2017 and Q1 2018 n=1101
Excludes patients with dublettes n=3
Total recruited n=2292
Lost to follow up with HRQOL forms                                                
n=1136
Curative follow-up HRQOL n=884              Response rate=55%
Palliative follow-up HRQOL n=267             Response rate=40%
Unknown treatment follow-up HRQOL= 5 
HRQOL available for analysis n=1156
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Table 2. Characteristics of all patients alive one year after oesophageal cancer diagnosis comparing those who completed 
European Organisation for Research and Treatment of Cancer the general questionnaire QLQ-C30 and the oesophageal 
module QLQ-OG25 and those who did not. Percentage within each category in brackets. 
 
 
Table 2 Curative intent Palliative intent 
 HRQoLa data HRQoLa data 
 Yes No Yes No 
Total 884  709 267 411 
Sex ratio (M: F) 683:201 559:150 193:74 299:112 
     
Age (years) 66 (29–93) 65 (20–89) 72 (37–91) 70 (21–95) 
     
WHO performance status 867 689 260 398 
0 493 (57) 406 (59) 69 (27) 124 (31) 
1 327 (38) 212 (31) 121 (47) 153 (38) 
2 44 (5) 65 (9) 56 (22) 87 (22) 
3 3 (0) 6 (1) 13 (5) 32 (8) 
4 0 0 1 (0) 2 
Missing  17 20 7 13 
     
 ASA fitness grade 871  697 259 400 
1 297 (34) 236 (34) 49 (19) 75 (19) 
2 443 (51) 338 (49) 107 (41) 163 (41) 
3 126 (14) 114 (16) 86 (33) 143 (36) 
4 5 (1) 9 (1) 17 (7) 19 (5) 
Missing 13 12 8 11 
     
Tumor location     
Proximal  53 (6) 45 (6) 14 (5) 33 (8) 
Middle      81 (9) 78 (11) 25 (9) 45 (11) 
Distal  643 (73) 502 (71) 169 (63) 237 (58) 
Not specified  107 (12) 82 (12) 24 (9) 95 (23) 
     
Tumor type  878  701 265 410 
Adenocarcinom 614 (70) 464 (66) 175 (66) 260 (63) 
SCCb 191 (22) 175 (25) 59 (22) 102 (25) 
Other 73 (8) 62 (9) 31 (12) 48 (12) 
     
Clinical T stage   884  708 267 410 
T0-T1 145 (16) 132 (19) 40 (15) 46 (11) 
T2-3 595 (67) 466 (66) 138 (52) 224 (55) 
T4 36 (4) 54 (8) 38 (14) 69 (17) 
Tx 108 (12) 56 (8) 51 (19) 71 (17) 
     
Clinical N stage 884 708 267 410 
  N0 529 (60) 382 (54) 104 (39) 136 (33) 
>N1 322 (36) 291 (41) 134 (50) 213 (52) 
  Nx 33 (4) 35 (5) 29 (11) 61 (15) 
     
Clinical M stage 883  707 267 406 
M0 851 (96) 673 (95) 155 (58) 214 (53) 
M1 16 (2) 19 (3) 110 (41) 181 (45) 
Mx 16 (2) 15 (2) 2 (1) 11 (3) 
 
Abbreviations: a) HRQoL= health related quality of life, b) SCC= squamous cell carcinoma 
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Table 3. Mean, adjusted mean score difference (MD) and 95% confidence intervals (CI) in Health-Related Quality of Life 
scores at one-year follow-up from Swedish National Registry including oesophageal cancer in patients who completed 
European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire and oesophageal module QLQ-
OG25 comparing patients with curative and palliative treatment intent and comparison in a Swedish reference population. 
 
 
 
 
 
Text in bold are clinically relevant and statistically significant 
 
 
 
Table 3 
All* 
n=1156 
Reference 
population 
n=4910 
Curative 
treatment 
n=884 
Palliative 
treatment 
n=267 
 
Curative 
compared to  
palliative 
adjusted 
 
QLQ-C30 Mean (CI) Mean (CI) Mean (CI) Mean (CI) MD (CI)  
Global health/QoL 60 (58 to 62) 76 (76 to 77) 61 (60 to 63) 55 (51 to 58) -8 (-11 to -4) 
Functions      
Physical function 73 (72 to 75) 88 (87 to 89) 76 (75 to 78) 64 (61 to 68) -11 (-14 to -7) 
Role function 64 (62 to 66) 88 (88 to 89) 66 (64 to 68) 56 (51 to 60) -13 (-18 to -8) 
Emotional function 75 (74 to 76) 86 (85 to 86) 76 (75 to 78) 71 (67 to 74) -8 (-11 to -4) 
Cognitive function 82 (80 to 83) 88 (88 to 89) 82 (81 to 84) 79 (76 to 82) -4 (-7 to -1) 
Social function 71 (69 to 72) 91 (91 to 92) 72 (70 to 74) 65 (61 to 69) -10 (-14 to -6) 
Symptoms      
Fatigue 43 (41 to 44) 19 (18 to 20) 41 (39 to 42) 49 (46 to 53) 10 (6 to 14) 
Nausea and vomiting 17 (15 to 18) 3 (2 to 3) 16 (15 to 18) 18 (15 to 21) 2 (-8 to 5) 
Pain 26 (25 to 28) 19 (18 to 20) 25 (23 to 27) 31 (27 to 35) 8 (4 to 12) 
Dyspnoea 36 (34 to 38) 16 (16 to 17) 35 (33 to 37) 41 (37 to 45) 8 (4 to 12) 
Insomnia 28 (26 to 30) 18 (17 to 18) 27 (25 to 29) 31 (27 to 35) 5 (1 to 10) 
Loss of appetite 30 (28 to 32) 3 (3 to 4) 28 (26 to 30) 38 (33 to 43) 10 (5 to 15) 
Constipation 14 (12 to 15) 5 (5 to 6) 11 (10 to 13) 22 (18 to 25) 10 (6 to 13) 
Diarrhoea 21(19 to 22) 6 (5 to 6) 23 (21 to 25) 13 (10 to 16) -9 (-13 to -5) 
Financial 14 (12 to 16) 4 (4 to 5) 14 (13 to 16) 13 (10 to 16) 4 (0 to 7) 
QLQ-OG25      
Function      
Body Image 72 (70 to 74)  74 (71 to 76) 67 (63 to 72) -7 (-12 to -3) 
Symptoms      
Dysphagia 24 (22 to 26)  22 (20 to 24) 32 (28 to 36) 11 (7 to 15) 
Eating 33 (32 to 35)  32 (30 to 34) 37 (33 to 41) 6 (2 to 10) 
Reflux 24 (22 to 25)  24 (23 to 26) 21 (18 to 25) -2 (-6 to 2) 
Odynophagia 20 (18 to 21)  19 (17 to 20) 23 (20 to 27) 6 (3 to 10) 
Pain and discomfort 26 (25 to 28)  26 (24 to 28) 27 (23 to 31) 3 (-1 to 7) 
Anxiety 46 (44 to 48)  44 (42 to 46) 52 (48 to 56) 10 (6 to 15) 
Eating with others 21 (19 to 22)  18 (16 to 20) 29 (25 to 34) 12 (8 to 17) 
Dry mouth 30 (28 to 32)  29 (26 to 31) 36 (32 to 40) 7 (2 to 11) 
Trouble with taste 24 (22 to 26)  22 (20 to 24) 31 (27 to 36) 10 (6 to 15) 
Trouble swallowing saliva 12 (11 to 14)  11 (10 to 13) 17 (13 to 20) 6 (2 to 9) 
Choked when swallowing 18 (16 to 19)  17 (15 to 19) 20 (16 to 23) 3 (-1 to 7) 
Trouble with coughing 31 (29 to 32)  30 (28 to 32) 31 (27 to 35) 1 (-3 to 5) 
Trouble talking 12 (10 to 13)  11 (10 to 13) 14 (11 to 17) 3 (-1 to 6) 
Weight loss 31 (29 to 33)  30 (28 to 33) 33 (29 to 38) 3 (-2 to 8) 
Hair loss 21 (18 to 24)  22 (18 to 25) 19 (13 to 25) -1 (-8 to 6) 
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Table 4. Mean, adjusted mean score difference (MD) and 95% confidence intervals (CI) in Health-Related Quality of Life 
scores at one-year follow-up from Swedish National Registry including oesophageal cancer who completed European 
Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire and oesophageal module QLQ-OG25 in 
patients stratified by clinical T-stage 
 
 
 
Text in bold are clinically relevant and statistically significant 
 
 
 
 
 
 
 
 
 
 
Table 4 
cT0-T1 
 
 
 
 
cT2-4   
Surgery 
 
 
cT2-4 
dCRT 
cT0-T1 
compared to 
cT2-4 
Surgery 
adjusted 
 
cT0-T1 
compared to 
T2-4 dCRT 
adjusted 
cT2-4 
Surgery 
compared to 
cT2-4 dCRT 
adjusted 
QLQ-C30 
Mean (CI) 
n (145) 
Mean (CI) 
n (539) 
Mean (CI) 
n (92) MD (CI) MD (CI) MD (CI) 
Global health/QoL 64 (60 to 69) 61 (59 to 63) 58 (53 to 64) -4 (-9 to 1) -6 (-13 to 2) -2 (-8 to 4) 
Functions       
Physical function 79 (76 to 82) 76 (74 to 78) 72 (67 to 77) -3 (-8 to 1) -6 (-12 to 0) -4 (-9 to 1) 
Role function 71 (66 to 76) 66 (63 to 69) 65 (59 to 71) -5 (-11 to 2) -5 (-14 to 4) -1 (-9 to 7) 
Emotional function 76 (72 to 80) 76 (75 to 79) 75 (70 to 79) 0 (-5 to 5) -3 (-10 to 3) -2 (-7 to 3) 
Cognitive function 83 (79 to 86) 83 (81 to 85) 79 (74 to 84) 0 (-4 to 4) -5 (-11 to 1) -4 (-9 to 0) 
Social function 76 (71 to 80) 72 (70 to 74) 70 (64 to 76) -4 (-9 to 2) -7 (-14 to 1) -3 (-9 to 4) 
Symptoms       
Fatigue 35 (31 to 40) 41 (39 to 44) 45 (39 to 50) 6 (1 to 12) 9 (1 to 16) 3 (-3 to 9) 
Nausea and vomiting 11 (8 to 15) 18 (16 to 20) 13 (9 to 18) 5 (0 to 9) 0 (-6 to 5) -5 (-10 to 0) 
Pain 27 (22 to 31) 25 (22 to 27) 25 (19 to 30) -3 (-8 to 3) -2 (-9 to 5) 2 (-4 to 8) 
Dyspnoea 31 (27 to 36) 35 (32 to 38) 36 (30 to 42) 5 (-1 to 11) 6 (-2 to 14) 1 (-6 to 8) 
Insomnia 24 (19 to 29) 29 (27 to 32) 23 (17 to 28) 3 (-3 to 9) -2 (-10 to 6) -6 (-13 to 1) 
Loss of appetite 20 (15 to 25) 29 (26 to 32) 30 (22 to 37) 10 (3 to 16) 7 (-2 to 16) 0 (-8 to 8) 
Constipation 12 (8 to 16) 11 (9 to 13) 14 (9 to 19) -2 (-6 to 3) 1 (-6 to 8) 3 (-2 to 8) 
Diarrhoea 21 (16 to 26) 26 (23 to 28) 11 (7 to 15) 3 (-3 to 8) -10 (-17 to -3) -14 (-20 to -8) 
Financial 11 (7 to 16) 15 (13 to 17) 14 (8 to 19) 1 (-4 to 6) 2 (-5 to 9) 1 (-5 to 7) 
QLQ-OG25       
Function       
Body Image 79 (74 to 84) 73 (70 to 76) 70 (63 to 78) -7 (-13 to 0) -9 (-18 to 0) -1 (-9 to 7) 
Symptoms       
Dysphagia 18 (13 to 23) 22 (19 to 24) 34 (27 to 42) 5 (-1 to 11) 16 (8 to 25) 11 (4 to 18) 
Eating 24 (20 to 28) 34 (32 to 36) 34 (28 to 40) 10 (5 to 15) 8 (1 to 16) -1 (-7 to 5) 
Reflux 23 (18 to 28) 25 (23 to 28) 20 (14 to 25) 2 (-3 to 8) -4 (-12 to 3) -8 (-14 to -1) 
Odynophagia 18 (13 to 22) 18 (16 to 20) 23 (18 to 29) -1 (-6 to 4) 3 (-4 to 10) 5 (0 to 11) 
Pain and discomfort 26 (22 to 31) 27 (25 to 29) 23 (17 to 28) 0 (-5 to 5) -5 (-12 to 3) -4 (-10 to 2) 
Anxiety 40 (35 to 44) 44 (42 to 47) 47 (39 to 54) 4 (-2 to 10) 7 (-1 to 16) 3 (-4 to 10) 
Eating with others 15 (10 to 20) 18 (16 to 21) 23 (17 to 29) 4 (-1 to 10) 9 (1 to 17) 4 (-3 to 11) 
Dry mouth 27 (22 to 32) 28 (26 to 32) 28 (21 to 35) 3 (-3 to 9) 2 (-6 to 11) -1 (-9 to 6) 
Trouble with taste 18 (13 to 22) 22 (19 to 25) 28 (21 to 35) 4 (-2 to 10) 9 (1 to 18) 6 (-1 to 13) 
Trouble swallowing saliva 8 (5 to 11) 12 (10 to 14) 14 (9 to 19) 3 (-2 to 7) 5 (-1 to 11) 2 (-4 to 7) 
Choked when swallowing 14 (11 to 18) 16 (14 to 18) 27 (20 to 35) 3 (-2 to 8) 13 (5 to 20) 10 (4 to 16) 
Trouble with coughing 28 (23 to 32) 31 (29 to 34) 32 (25 to 39) 3 (-3 to 9) 1 (-7 to 10) 0 (-7 to 7) 
Trouble talking 9 (6 to 13) 11 (9 to 13) 19 (12 to 25) 5 (0 to 9) 13 (6 to 20) 5 (-1 to 10) 
Weight loss 19 (14 to 24) 34 (31 to 37) 27 (20 to 34) 18 (11 to 25) 9 (1 to 17) -8 (-16 to 0) 
Hair loss  23 (12 to 36) 21 (17 to 26) 23 (11 to 36) -5 (-18 to 9) -9 (-28 to 10) -3 (-15 to 10) 
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Table 5. Mean, adjusted mean score difference (MD) and 95% confidence intervals (CI) in Health-Related Quality of Life 
scores at one year follow-up from Swedish National Registry including oesophageal cancer who completed European 
Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire and oesophageal module QLQ-OG25 in 
patients stratified by reason for palliative intention.  
 
 
    Table 5                                                                       Incurable due to                                      Mean score difference  
 
 
 
 
M1 
 
n=110 
 
 
Tumour 
stage 
T4 
n=22 
Non-tumour- 
related 
reasonsa 
 
n=135 
 
M1  
compared to  
T4 
 
adjusted 
M1  
compared to 
non-tumour- 
related 
reasonsa 
 
adjusted 
T4  
compared to  
non-tumour- 
related 
reasonsa 
 
adjusted 
 
QLQ-C30 Mean (CI) Mean (CI) Mean (CI) MD (CI) MD (CI) MD (CI)  
Global health/QoL 54 (48 to 60) 49 (34 to 64) 56 (51 to 61) -4 (-11 to 11) 2 (-6 to 11) 5 (-9 to 19)  
Functions        
Physical function 65 (59 to 70) 62 (48 to 77) 65 (60 to 69) 0 (-14 to 15) 1 (-7 to 9) 1 (-12 to 15)  
Role function 53 (46 to 60) 52 (36 to 69) 59 (53 to 65) -1 (-19 to 18) 4 (-7 to 15) 3 (-15 to 21)  
Emotional function 69 (64 to 74) 76 (65 to 87) 71 (67 to 75) 7 (-6 to 21) 0 (-8 to 7) -8 (-20 to 4)  
Cognitive function 79 (74 to 84) 81 (71 to 92) 79 (75 to 83) 3 (-9 to 15) -1 (-7 to 6) -2 (-13 to 9)  
Social function 60 (54 to 66) 56 (40 to 73) 71 (66 to 76) -3 (-19 to 13) 7 (-2 to 16) 10 (-4 to 24)  
Symptoms        
Fatigue 50 (44 to 55) 51 (36 to 65) 49 (44 to 54) 0 (-15 to 15) 2 (-7 to 11) 1 (-13 to 16)  
Nausea and vomiting 18 (13 to 23) 18 (7 to 29) 17 (13 to 21) 4 (-16 to 9) -1 (-9 to 6) 3 (-8 to 15)  
Pain 32 (25 to 38) 31 (17 to 45) 31 (26 to 36) -2 (-19 to 14) -1 (-10 to 8) 3 (-11 to 17)  
Dyspnoea 42 (36 to 49) 44 (30 to 59) 40 (34 to 45) 4 (-13 to 21) 0 (-10 to 10) -5 (-22 to 12)  
Insomnia 30 (24 to 36) 38 (23 to 53) 30 (24 to 36) 7 (-9 to 23) 3 (-6 to 12) -2 (-18 to 14)  
Loss of appetite 38 (30 to 45) 44 (28 to 61) 37 (30 to 43) 1 (-19 to 21) 3 (-8 to 14) 1 (-17 to 19)  
Constipation 20 (14 to 26) 20 (7 to 32) 23 (18 to 29) -3 (-18 to 13) 4 (-6 to 13) 6 (-10 to 21)  
Diarrhoea  12 (7 to 16) 12 (4 to 21) 14 (9 to 18) 0 (-12 to 11) 4 (-3 to 11) 3 (-8 to 15)  
Financial 16 (11 to 21) 9 (-1 to 19) 11 (7 to 15) -5 (-17 to 8) 1 (-7 to 8) 6 (-5 to 17)  
QLQ-OG25        
Function        
Body image 64 (57 to 71) 67 (48 to 85) 70 (64 to 76) 2 (-17 to 21) 5 (-5 to 16) 4 (-13 to 21)  
Symptoms        
Dysphagia 34 (27 to 40) 51 (34 to 67) 28 (23 to 33) 8 (-9 to 25) -7 (-16 to 3) -18 (-33 to -3)  
Eating 38 (32 to 44) 45 (30 to 61) 35 (30 to 41) 2 (-14 to 18) 0(-9 to 9) -5 (-20 to 10)  
Reflux 22 (16 to 27) 23 (8 to 38) 21 (16 to 26) -2 (-17 to 12) -2 (-11 to 6) 1 (-13 to 15)  
Odynophagia 22 (17 to 28) 27 (13 to 40) 24 (19 to 29) 0 (-14 to 14) 4 (-4 to 13) 4 (-10 to 18)  
Pain and discomfort 26 (20 to 32) 29 (18 to 41) 28 (23 to 34) 3 (-13 to 18) 7 (-3 to 16) 7 (-8 to 22)  
Anxiety 52 (46 to 59) 52 (36 to 67) 52 (46 to 57) -3 (-21 to 14) 1 (-9 to 10) 3 (-13 to 19)  
Eating with others 33 (26 to 40) 30 (14 to 46) 26 (20 to 32) -7 (-26 to 11) -5 (-16 to 6) 2 (-15 to 19)  
Dry mouth 40 (32 to 48) 22 (6 to 38) 35 (29 to 40) -24 (-45 to -4) -5 (-16 to 5) 15 (-1 to 31)  
Trouble with taste 37 (29 to 45) 32 (16 to 47) 26 (20 to 32) -5 (-25 to 15) -5 (-16 to 6) -3 (-19 to 14)  
Trouble swallowing 
saliva 
20 (14 to 26) 14 (-1 to 29) 14 (10 to 19) -11 (-27 to 4) -9 (-18 to -1) 0 (-13 to 13)  
Choked when 
swallowing 
19 (13 to 25) 23 (10 to 36) 20 (15 to 25) 2 (-14 to 17) 3 (-6 to 9) -1 (-15 to 13)  
Trouble with coughing 27 (21 to 33) 29 (12 to 46) 35 (29 to 40) -3 (-18 to 13) 7 (-2 to 16) 8 (-8 to 23)  
Trouble talking 16 (11 to 22) 17 (5 to 28) 12 (8 to 16) -3 (-17 to 10) -5 (-13 to 3) -3 (-14 to 9)  
Weight loss 35 (28 to 42) 27 (10 to 44) 32 (26 to 39) -15 (-33 to 4) -1 (-12 to 10) 10 (-8 to 28)  
Hair loss 27 (18 to 36) 18 (-3 to 39) 10 (3 to 17) -5 (-29 to 18) -13 (-26 to 0) 2 (-18 to 21)  
 
Text in bold are clinically relevant and statistically significant 
 
5.2 PAPER II 
 
Patients included at diagnosis, during and after neoadjuvant treatment 
During the study period, 43 patients were screened for inclusion and 35 patients were 
included and assessed at baseline and after the first cycle of chemotherapy. Because of side-
effects during treatment, only 32 patients remained and were followed until surgery. In 
addition, 24 patients completed chemoradiotherapy versus 8 patients completed 
neoadjuvant chemotherapy (Table 6).  
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Comparisons of dysphagia, appetite and weight between baseline and first chemotherapy 
cycle 
A statistically significant relief of dysphagia with both Ogilvie score (1.89 to 1.06) and 
Watson scale (27.03 to 16.46) was detected (p<0.001). Also, appetite scale (3.83 to 2.6, 
p<0.03) significantly improved already after first cycle of chemotherapy in the whole 
cohort. Patients remained weight stable after first chemotherapy cycle (77 kg, p=1.00) 
(Table 7). 
 
Baseline assessment of dysphagia, meaning that the majority of the patients only being able 
to intake fluids and the rest restricted to eating minced food. 
The relief of dysphagia after completion of cycle one, corresponded to being able to eat 
more solid food (vegetables, potatoes, fish, bread and pasta) and more than 40% of the 
patients were also able to eat meat (data not shown). 
 
Comparisons of dysphagia, appetite and weight during treatment 
Further statistically significant (p<0.001) relief of symptoms was detected after completed 
neoadjuvant therapy measured with both Ogilvie score (1.89 to 0.63) and Watson scale 
(27.03 to 9.41). However, appetite was not significantly improved in comparison with 
baseline (3.83 to 2.91, p=0.11) and after completion of neoadjuvant therapy before surgery, 
comparing the whole cohort. Patients remained weight stable during the treatment period 
(77 kg) (Table 7). 
 
Also, after completion of neoadjuvant treatment before surgery patients reported that 
dysphagia was further relieved, with 60% of the patients studied being able to eat meat 
(data not shown).  
 
Relief of dysphagia, appetite and weight in subgroups treated with nCT and nCRT 
Only 8 patients completed neoadjuvant chemotherapy, and dysphagia was only improved 
significantly with Ogilvie score (1.7 to 0.62, p=0.03). Patients remained weight stable (77 
kg) and appetite improved but not significantly during treatment period (3 to 1.5, p=0.07). 
However, in the neoadjuvant chemoradiotherapy group including 24 patients, both Ogilvie 
score (2 to 0.65, p<0.001) and Watson scale (29.27 to 8.75, p<0.001) significantly 
improved. No significance was detected regarding weight over time (77 kg, p=0.71) but 
appetite improved from 4.33 to 3.52 (p=0.03) (Table 7). 
 
Dysphagia response and histological response 
No association between the presence of histological response, the degree of response and 
relief of dysphagia was detected.  (Watson, p=0.466 and Ogilvie, p=0.181) (Fig 6). 
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Table 6. Characteristics of 35 patients included in the analysis 
 
Characteristics n (%) 
Included 35(100)   
Gender 
 
Male 32 (91) 
Female  3 (9)   
Histology 
 
Adenocarcinomas 29 (83) 
Squamous cell carcinoma  6 (17) 
  
Tumor location  
Oesophagus 22(63) 
Gastroesophageal junction 13(37)   
Neoadjuvant treatment 
 
Chemotherapy 10 (29) 
Chemoradiotherapy 25 (71)   
Clinical T-stage 
 
T2  5 (14) 
T3 30 (86)   
Clinical N-stage 
 
N0 14 (40) 
N1 16 (46) 
N2 5 (14) 
 
 
 
 
 
 
  
 
 
 
Fig. 6 Correlation between dysphagia development during and after neoadjuvant therapy (Watson, Ogilvie) 
and histological tumor response according to Chirieac. A-7, B-4, C-3, D-16. 
 
 
 
Ogilvie
Chiriaec
P=0.181
Watson
Chiriaec
P=0.446
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Table 7. Development of dysphagia, weight, and appetite during neoadjuvant therapy 
 
  
Baseline After 
Chemo-
therapy  
cycle 1 
P-valuea After 
completed 
neoadjuvant 
therapy 
P valueb P-value c 
All patients 
      
Included Patients 35 35 
 
32 
  
Weight (mean) 77.33 77.38 1,00 76.79 0.84 0.94 
Appetite score 3.83 2.6 0.03 2.91 1 0.11 
Dysphagia score 
      
Ogilvie 1.89 1.06 <0.001 0.63 0.081 <0.001 
Watson 2.,03 16.46 <0.001 9.41 0.06 <0.001        
Chemoradiotherapy 
     
Included Patients 25 25 
 
24 
  
Weight (mean) 77.4 77.5 1.00 76.6 0.45 0.70 
Appetite score 4.33 2.7 0.03 3.52 0.59 0.03 
Dysphagia score 
      
Ogilvie  2 1 <0.01 0.65 0.27 <0.001 
Watson 29.27 16.45 <0.01 8.75 0.01 <0.001        
Chemotherapy 
      
Included Patients 10 10 
 
8 
  
Weight (mean) 77.2 76.9 1.00 77.3 1.00 1.00 
Appetite score 3 2.6 1 1.5 0.48 0.07 
Dysphagia score 
      
Ogilvie 1.7 1.1 0.14 0.62 0.38 0.03 
Watson 22.55 14.55 0.19 9.87 0.87 0.11 
 
a) p-value for difference between baseline and after cycle one, b) p-value for difference between after cycle 
one and after completed neoadjuvant therapy, c) p-value for whole treatment period from baseline to after 
complete neoadjuvant therapy. Repeated measurement analysis of variance was used for significance testing.  
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5.3 PAPER III  
This paper presents dysphagia analysis in the NeoRes trial, a secondary endpoint outcome 
measurement. A total of 181 patients were randomised between 2006 and 2013, 91 patients 
were allocated to neoadjuvant chemotherapy and 90 patients to neoadjuvant 
chemoradiotherapy. In this study 134 patients were included at baseline and 98 patients at 
the end of treatment. The aim was to evaluate dysphagia response during neoadjuvant 
treatment, thus patients with stent insertion were excluded (20 patients) from the primary 
analysis (Figure 7). Assessment of dysphagia were extracted by use of validated 
questionnaires applied in the trial. Characteristics of the included patients is presented in 
table 8, and considered to be balanced between subjects that responded versus not 
responded to dysphagia questionnaires. 
 
Changes of swallowing problems within treatment groups 
In comparison within treatment allocation, among patients with dysphagia at baseline 
treated with nCT, they reported relief of dysphagia after completion neoadjuvant treatment. 
This was detected both clinically relevant and statistically significant (MD -16, 95% ci: -29 
to -4, p=0.012). In patients without dysphagia they reported no changes. In addition, 
patients reported improved ability to eat solid food and minced food, both detected with 
clinical relevance and statistical significance. In patients treated with nCRT they also 
reported relief of dysphagia after completion of neoadjuvant therapy, both clinically 
relevantly and statistically significantly (MD -13, 95% ci: -25 to -1, p=0.039) improvement. 
In addition, improved ability to eat solid food were reported, this was both clinically 
relevant and statistically significant. However, in patients treated with nCRT and who 
reported no dysphagia at baseline deterioration were reported after completion of nCRT 
treatment. This was detected both clinically relevant and statistically significant (MD 17, 
95% ci: 8 to 25 p<0.001) (Table 9). 
 
Differences of dysphagia in comparisons between nCT and nCRT 
No significantly difference were reported in comparison between allocated groups in 
patients who reported dysphagia at baseline. However, in comparison between groups 
among patients without dysphagia at baseline, a clinically relevant and statistically 
significant difference were reported with more dysphagia after ended nCRT treatment (MD 
14, 95% ci: 3 to 25, p=0.014) (Table 10). 
 
Nutritional considerations 
Patients treated with nCT were weight stable when compared between baseline and before 
surgery (81 kg), while patients treated with nCRT loosed three kilograms when measured at 
baseline and before surgery (80 versus 77 kg). Nutritional treatment differed significantly 
between the groups, patients treated with nCRT were provided with more gastrostomies 
compared to those treated with nCT (20 versus 8, p=0.05). Also, management with orally 
feeding only was lower in patients with nCRT (56% versus 77%, p=0.05) compared to nCT 
(Table 11). 
 
Comparisons between responses of dysphagia and histological responses 
When investigated whether any correlation was detected between histological response and 
clinical T-stage, using histopathological stage and dysphagia scoring prior and after ended 
treatment, no statistically significant association between dysphagia response and 
histological response (p=0.204) were reported. In addition, dysphagia did not differ among 
those with complete response (TRG1) versus those with lack of any response (TRG4) 
(p=0.583) (Table 12). 
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Figure 7. CONSORT all patients included in the NeoRes trial and completed dysphagia questionnaires 
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Table 8. Characteristics were similar in comparison with the whole cohort and between 
treatment allocations  
All patients who completed European of Research and Treatment of Cancer (EORTC) dysphagia questions in 
QLQ-OES24/OG25, and excluded patients with stent 
a) Clinical tumor stage, T refers to the size and extent of the main tumor and N refers to the number of nearby 
lymph nodes that have cancer b) WHO performance status range 0-4  
nCT= neoadjuvant chemotherapy, nCRT= neoadjuvant chemoradiotherapy 
  
Table 8 
                                                            
All patients randomised  
Subgroup of patients who 
completed dysphagia questions    
     
 nCT (%) nCRT (%) nCT (%) nCRT (%)  
Eligible 91(100) 90(100) 69(89) 65(85) 
Gender     
Female 14(15) 18(20) 10(14) 14(22) 
Male 77(85) 72(80) 59(86) 51(78) 
     
Age in years median (Range) 63(37–75) 63(38–74) 62(39–75) 63(42–74) 
Histology at diagnosis     
Adenocarcinoma 66(73) 65(72) 51(74) 47(72) 
SCC 25(27) 25(28) 18(26) 18(28) 
     
Clinical TN-Stage a     
T1   1(1)   1(1)   1(1)   0(0) 
T2 31(34) 31(34) 22(32) 20(31) 
T3 59(65) 58(64) 46(67) 45(69) 
     
N0 34(37) 33(37) 26(38) 21(32) 
N-positive 57(63) 57(63) 43(62) 44(68) 
     
WHO performance statusb      
0 77(85) 75(83) 59(86) 53(82) 
1 14(15) 15(17) 10(14) 12(18) 
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Table 9. EORTC QLQ OES24/OG25, self-reported dysphagia symptom score, both before and after neoadjuvant 
treatment by allocated treatment among patients with cancer of the oesophagus and GOJ returning questionnaires 
at both timepoints 
 
 
 
Self-reported comparison of dysphagia before and after neoadjuvant treatment in all study participants who completed 
dysphagia items both before and after treatment and reporting dysphagia at baseline. a) Items included in dysphagia scale. 
Trial allocations b) nCT= neoadjuvant chemotherapy and nCRT= neoadjuvant chemoradiotherapy.   
 
Table 9 
 
 
Number of patients 
Before neoadjuvant 
treatment 
mean score 
(ci) 
After neoadjuvant 
treatment 
mean score       
(ci) 
 
Mean score 
difference 
(ci) 
p-value 
Neoadjuvant chemotherapy 
No dysphagia at baseline 
 
17 
 
0 (0–0) 
 
3 (-2-7) 
      
3 (-5-10) 
 
0.216 
Dysphagia at baseline  29 42 (32–51) 25 (12–39) -16 (-29--4) 0.012 
      Problem to eat solid food a  29 60 (49–71) 31 (16–47) -29 (-43--14) <0.001 
      Problem to eat minced food a 28 44 (32–56) 27 (12–43) -18 (-34- -2) 0.030 
      Problem to drink a  29 22 (10–33) 18 (5–31) -3 (-18-11) 0.630 
      
Neoadjuvant chemoradiotherapy      
No dysphagia at baseline 14 0 (0–0) 17 (5–28) 17 (8–25) <0.001 
Dysphagia at baseline  31 41(31–50) 28 (17–39) -13 (-25--1) 0.039 
     Problem to eat solid food a  30 58 (47–68) 36 (23–49) -22 (-36--8) 0.003 
     Problem to eat minced food a 30 37 (24–49) 28 (13–42) -9 (-24-6) 0.242 
     Problem to drink a 29 22 (10–33) 18 (9–27) -5 (-19-10) 0.521 
      
   The European Organization for Research and Treatment of Cancer (EORTC) Esophageal modules QLQ-OES24/OG25.  Data is presented with 
means and mean score differences and 95% confidence (ci) intervals. All data analyzed with linear regression with prediction by arm. Scores are 
between 0-100 a high score= high level of symptoms. A mean score difference of 10 points or more was defined as a clinically relevant 
difference. Patients supported with stents are excluded from analysis. Self-reported comparison of dysphagia before and after neoadjuvant 
treatment in all study participants who completed dysphagia items both before and after treatment and reporting dysphagia at baseline. a) Items 
included in dysphagia scale.  
 
 
Table 10. Comparison of dysphagia score between arms, regarding mean score difference between before and after neoadjuvant 
treatment  
 
Table 10. Comparison of dysphagia scores between arms, regarding 
mean score difference between before and after neoadjuvant treatment 
 Number of 
patients 
nCTb                 
mean score      
difference 
nCRTb             
mean score    
difference 
Difference 
between arms 
p-value 
No dysphagia  31 3 (-2-7) 17 (8-25) 14 (3-25) 0.014 
Dysphagia  60 -16 (-29-- 4) -13 (-25--1)   4 (-14-21) 0.686 
     Problem to eat solid food a  59 -29 (-43--14) -22 (-36- -8)   7 (-14-27) 0.519 
     Problem to eat minced food a 56 -18 (-34--2) -9 (-24-6)   9 (-13-31) 0.415 
     Problem to drink a  58 -3 (-18 -11) -5 (-19 -10) -1 (-21-19) 0.910 
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Table 11. Nutritional support and weigh changes among 152 patients with cancer of esophagus or GOJ and 
randomised in the NeoRes trial who completed EORTC QoL-OES24/OG25 baseline dysphagia questionnaire 
 
  
Table 12. Comparison between histological response and clinical T-stage (cT), histopathologic (pT)-stage and 
dysphagia scoring prior to and after neoadjuvant treatment among patients with cancer of the esophagus or 
GOJ 
 
a) cT-stage is Clinical T-stage, comparing, Chi square test used to compare TRG1 and TRG4 
b) pT-stage is histopathologic T-stage defined by tumour regression grade according to Chireac (TRG), 
comparing The Chi-square test used to compare TRG1 and TRG4 
Health Related Quality of Life (HRQoL), the dysphagia items on the European Organisation for Research and 
Treatment of Cancer (EORTC) QLQ-OES24/OG25 before and after neoadjuvant treatment among patients 
with surgery. Wilcoxon rank sum test used to compare TRG1 and TRG4 CI=confidence interval  
Table 11 
 nCT nCRT p-value 
152 patients:     
Albumin baseline mean (range)  40 (17–50) 40 (30–66)  0.516 
Weight (kg) baseline mean (range)  81 (50–117)  80 (42–122)  0.559 
Weight (kg) presurgery mean (range)   81 (48–122)  77 (42–121) 0.363 
BMI baseline  26 (17–38) 26 (17–34)  0.477 
BMI after treatment  26 (18–38) 25 (16–34)  0.455 
Nutritional treatment from baseline until surgery:   0.012 
Oral 61 (77) 40 (56)  0.005 
Gastrostomy 8 (10) 20 (28)  0.005 
Clinifeeding tube 4 (5) 8 (11)  0.231 
Parenteral 6 (8) 4 (6)  0.433 
    
Stent 11(14) 7(10)  0.426 
    
Data are presented as mean and numbers. Discrepancies between the arms in patients with Gastrostomy (PEG) 
is primarily because of when the trial started in 2006, at one site the patients allocated with nCRT were 
prepared with PEG before treatment.  Patients treated with stents included in the table. Albumin and nutritional 
treatments are analysed by Chi-square test and Fischer Exact Test. Weight (kg) and BMI is analysed using 
Mann Whitney U Test   
    
 
All patients with surgery n obs 
TRG1                  
n (%) 
TRG2           
n(%) 
TRG3        
n(%) 
TRG4        
n(%) 
p-value              
TRG1 vs 
TRG4 
cT-stage a      0.262 
T2 56   9 (31)   5 (21)   6 (32) 36 (43)  
T3 100 20 (69) 17 (79) 13 (68) 48 (57)  
       
pT-stage b      <0.001 
ypT0 29 29 (100)   0 (0)   0 (0)   0 (0)  
ypT1 27   0 (0) 11 (46)   4 (21) 12 (14)  
ypT2 23   0 (0)   4 (17)   4 (21) 15 (18)  
ypT3 70   0 (0)   8 (33) 11(58) 51 (61)  
ypT4 7   0 (0)   1 (4)    0 (0)   6 (7)  
       
Prior to therapy dysphagia mean score (CI) 119 25 (15 - 34) 29 (12 - 45) 37 (19 - 55) 26 (19 - 33) 0.803 
Post therapy dysphagia mean score (CI)  88 20 (6 - 34) 23 (8 - 38) 18 (-1 - 37) 20 (12 - 28) 0.583 
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5.4 PAPER IV 
 
A total of 285 patients were screened for eligibility in the NeoRes trial between October 
2006 and February 2013. Of these, 181 met the inclusion criteria and signed informed 
consent forms to participate in the trial. At randomisation, patients were allocated to either 
neoadjuvant chemotherapy (n=91) or to neoadjuvant chemoradiotherapy (n=90) plus 
surgery. Baseline characteristics were balanced between the allocated groups. (See table 13) 
In total 165 patients were included in HRQoL analysis, and 154 patients completed baseline 
questionnaires and 113 patients after ended neoadjuvant treatment, see CONSORT (Figure 
8), regarding HRQoL completion rates during follow up in the trial. 
 
HRQoL before neoadjuvant treatment 
 At inclusion, patients reported lower scores in several functions (especially role, emotional 
and social), global health/QoL was low and several symptoms were scored high (fatigue, 
insomnia, loss of appetite, dysphagia, eating problems, odynophagia and anxiety of future 
health) (Table 14). 
 
HRQoL after ended neoadjuvant treatment before surgery 
Differences in comparison between allocation, was that patients reported more problems 
with appetite loss and this were clinical relevantly higher when given nCRT, but did not 
reach statistical significance. While problems of pain when swallowing (odynophagia) were 
relieved both clinically relevant and statistically significant when treated with nCT (MD 11, 
95% ci: 0 to 22, p=0.047) compared to nCRT (Table 15). 
 
Changes were reported within groups in comparisons with baseline. Patients reported 
several functions were further decreased after neoadjuvant treatment. However, clinically 
and statistically significant changes were observed regarding global health/QoL, physical, 
role and social function when treated with nCRT, but this was not reported in the nCT 
group. In addition, after neoadjuvant treatment especially some oesophagus related 
symptoms were relieved after neoadjuvant treatment in both groups. Especially, treatment 
with nCT reported changes with fewer troublesome eating problems, odynophagia and 
anxiety of future health, in contrast other symptoms deteriorated (fatigue, dry mouth and 
trouble with taste). Also, in the nCRT group symptoms were relieved (problems with 
choking and odynophagia), while other symptoms worsen (fatigue, nausea and vomiting, 
dyspnoea, appetite loss, financial difficulties and trouble with taste). All reported symptoms 
were changed both clinically relevant and statistically significant (Figure 9a).   
 
HRQoL one year after surgery  
In comparison between allocation no clinically or statistically significantly differences were 
revealed at one-year follow-up after surgery. However, between treatment groups patients 
treated with nCRT reported more clinically relevant more problem with dry mouth (MD 11, 
95% ci: -3 to 25, p=0.123), but without statistical significance (Table 15). 
 
Changes were reported within both groups in comparisons with baseline. Patients treated 
with nCT reported decreased physical function. Regarding symptoms patients reported 
improvements (trouble with sleeping and constipation) and conversely (dyspnoea, 
diarrhoea, reflux and trouble with talking) became worse. In addition, patients treated with 
nCRT reported decreased physical function. Among symptoms odynophagia improved, but 
dyspnoea and dry mouth became worse. All reported symptoms and physical function were 
detected with clinically relevance and statistically significance in both groups (Figure 9b).  
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HRQoL three years after surgery  
Differences were reported between allocations at three years follow up, with better HRQoL 
in several aspects if treated with nCT compared to nCRT. Social functioning was clinically 
lower when treated with nCRT (MD -10 (95% ci: -23 to 4, p=0.159)) compared to nCT, but 
did not reach statistically significance. In addition, more problems were reported with 
dyspnoea (MD12 (95% ci: -1 to 27, p=0.067)) and problems with coughing (MD 17 (95% 
ci: 4 to 30, p=0.011)) both being clinically more affected when treated with nCRT 
compared to nCT. Although, coughing was also statistically significant (Table 15). 
 
Changes were reported within both groups in comparisons with baseline. Patients treated 
with nCT reported no change in functions, while symptoms (insomnia, constipation and 
anxiety of future health) were improved. Reflux was the only reported problem that 
remained at three years follow up compared to baseline. Although, in the nCRT group 
patients reported lower levels of physical function and several worsen symptoms 
(dyspnoea, diarrhoea, reflux and trouble with cough) at three years follow up. In addition, 
patients also reported improved problems (dysphagia and odynophagia) when treated with 
nCRT. All reported symptoms and physical function were both with clinically relevant and 
statistically significant in both allocated treatment groups (Figure 9c). 
 
HRQoL  five years after surgery  
In direct comparison between treatment allocation, several clinically relevant differences 
were reported but neither were statistically significant. Patients treated with nCRT they 
reported worsen functions and symptoms compared to nCT. Firstly, both role function (MD 
-12, 95% ci: -33 to 9, p=0.237) and social function (MD -11, 95% ci: -27 to 7, p=0.246) 
were lower compared to nCT. Secondly, among known treatment related side-effects more 
problems with fatigue (MD 10, 95% ci: -7 to 26, p=0.244) and dyspnoea (MD 16, 95% ci: -
2 to 34, p=0.085) were reported. Lastly, among known oesophageal side-effects troubles 
with swallowing saliva (MD 13, 95% ci: -5 to 30, p=0.165), dry mouth (MD 18, 95% ci: -2 
to 37, p=0.075) and trouble with taste (MD 10, 95% ci: -8 to 27, p=0.271) were more 
severe compared to nCT (Table 15).   
 
Few changes were reported at five years follow up in comparisons with baseline. In 
functions no changes were reported in either group. Although, patients reported worsen 
problems with dyspnoea and reflux when treated with nCRT and both were clinically 
relevant and statistically significant (Figure 9d).  
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Figure 8. CONSORT diagram included patients in NeoRes trial and completed follow-up of patient reported 
outcomes using the European Organisation for Research and Treatment of Cancer (EORTC) core 
questionnaire QLQ-C30 and the esophageal module. Abbreviations: nCT=neoadjuvant chemotherapy, nCRT= 
neoadjuvant chemoradiotherapy 
 
 
 
 
CONSORT diagram health-related quality of life 
in NeoRes trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
285 assessed for eligibility 
 
181 randomized 
 
104 excluded 
50 did not meet inclusion criteria  
36 refused to participate 
18 other reasons 
91 allocated to nCT  
80 completed  baseline PRO  (90% 80 of 89) 
     
 10 did not complete baseline PRO  
 
 
90 allocated to nCRT  
74 completed baseline PRO (86% 74 of 86) 
 
14 did not complete baseline PRO  
 
Excluded at baseline:  
1 consent withdrawal 
1 outside window bl 
 
Excluded during nT: 
6 excluded due to toxicity 
3 progressive disease excluded 
3 excluded outside window 
 
 
After nCT=13 not operated 
 
 Excluded at baseline:  
1 consent withdrawal 
2 outside window  
1 no date 
 
Excluded during nT:  
1 consent withdrawal 
7 excluded due to toxicity 
4 progressive disease 
3 outside window after nT 
 
After nCRT= 11 not operated 
 
  
40 completed PRO 1 year (82% 40 of 49)  
34 completed PRO 3 year  (83% 34 of 41)  
24 completed PRO 5 year (73% 24 of 33)  
 
 
29 completed PRO 1 year (59% 29 of 49)  
29 completed PRO 3 year (73% 29 of 40)  
20 completed PRO 5 year (56% 20 of 36)   
 
57 completed PRO after ended 
neoadjuvant treatment  
(73% 57 of 78)  		
56 completed PRO after ended 
neoadjuvant treatment  
 (74%  56 of 76) 
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Table 13. Baseline characteristics overall between neoadjuvant chemotherapy (nCT) and neoadjuvant 
chemoradiotherapy (nCRT) and of the subgroup of patients who completed health related quality of life 
instruments (HRQoL) the European Organisation for Research and Treatment of Cancer (EORTC) core 
questionnaire QLQ-C30 and the oesophageal module. 
 
 
 Table 13 All patients randomised  Subgroup of patients who 
completed  
HRQoL   
  nCT (%) nCRT (%) nCT (%) nCRT (%) 
Total 91 (100) 90 (100) 80 (90) 74 (85) 
Male gender 77 (85) 72 (80) 68 (85) 60 (81) 
Age in years median (Range) 63 (37–75) 63 (38–74) 63 (37–75) 64 (38–74) 
Histology at diagnosis         
Adenocarcinoma 66 (73) 65 (72) 59 (74) 54 (73) 
SCC 25 (27) 25 (28) 21 (26) 20 (27) 
Clinical T and N-Stage          
T1   1 (1)   1 (1)   1 (1)   1 (1) 
T2 31 (34) 31 (34) 24 (30) 23 (31) 
T3 59 (65) 58 (64) 55 (69) 50 (67) 
N0 34 (37) 33 (37) 26 (32) 25 (34) 
N-positive 57 (63) 57 (63) 54 (68) 49 (66) 
Tumor location         
Proximal    2 (2)   2 (2) 1 (1) 1 (1) 
Middle 13 (14) 13 (14) 11 (14) 11 (15) 
Distal 59 (65) 61 (68) 51 (64) 51 (69) 
GOJ 17 (19) 14 (15) 16 (20) 11 (15) 
WHO performance status a         
0 77 (85) 75 (83) 67 (84) 61 (82) 
1 14 (15) 15 (17) 13 (16) 13 (18) 
 
a) WHO performance status from 0-4, the lower score denotes a better functional status.  
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Table 14. Baseline HRQoL mean scores by allocated treatment and mean differences between groups. Mean 
differences (MD), 95% confidence intervals (ci) and p-value for all patients who completed the European 
Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 and the oesophageal 
module.  
 
 
 
Data are presented as mean scores scores with 95% confidence intervals (ci) with a mean score differece (MD) 
between allocation before start of treatment. HRQoL scores indicators in the range of 0 to 100, with higher 
scores in function/symptoms indicating a better/worse state 
  
Table 14 Neoadjuvant 
chemotherapy 
Neoadjuvant 
chemoradiotherapy 
Mean difference  
QLQ-C30 Mean (95% ci) 
n (80) 
Mean (95% ci) 
n (74) 
 MD (95% ci) 
n (154) 
Global health/QoL 67 (62 to 72) 69 (63 to 74) 2 (-6 to 9) 
Function       
Physical functioning 88 (84 to 92) 90 (87 till 93) 3 (-4 to 7) 
Role functioning 73 (66 to 80) 77 (69 to 84) 4 (- 6 to 14) 
Emotional functioning 72 (67 to 77) 78 (73 to 82) 5 (-1 to 12) 
Cognitive functioning 87 (83 to 91) 88 (84 to 92) 1 (-5 to 7) 
Social functioning 78 (72 to 84) 76 (70 to 83) -2 (-10 to 7) 
Symptoms       
Fatigue 29 (23 to 34) 27 (22 to 33) -1 (-9 to 7) 
Nausea and vomiting 10 (6 to 14) 12 (7 to 16) 2 (-4 to 8) 
Pain 24 (18 to 29) 19 (13 to 24) -5 (-13 to 3) 
Dyspnoea 17 (11 to 23) 13 (7 to 19) -4 (-13 to 4) 
Insomnia 30 (23 to 36) 27 (21 to 34) -2 (-12 to 7) 
Loss of appetite 29 (22 to 36) 29 (21 to 36) 0 (-11 to 10) 
Constipation 21 (15 to 26) 15 (9 to 21) -6 (-14 to 2) 
Diarrhoea 10 (5 to 16) 10 (4 to 15) -1 (-9 to 7) 
Financial difficulty 14 (8 to 20) 8 (2 to 14) -6 (-14 to 3) 
QLQ-OES24/OG25       
Dysphagia 28 (22 to 34) 31 (25 to 37) 3 (-5 to 12) 
Eating 37 (31 to 43) 39 (33 to 45) 2 (-6 to 11) 
Reflux 11 (6 to 16) 15 (10 to 20) 4 (-3 to 11) 
Trouble swallowing saliva 14 (8 to 20) 15 (9 to 22) 2 (-7 to 10) 
Choking 18 (13 to 23) 19 (13 to 25) 1 (-7 to 9) 
Dry mouth 15 (8 to 21) 21 (15 to 28) 7 (-2 to 16) 
Trouble with taste 8 (2 to 14) 10 (4 to 16) 2 (-6 to 10) 
Trouble with coughing 14 (8 to 19) 19 (13 to 25) 5 (-3 to 13) 
Trouble talking 3 (-1 to 7) 7 (3 to 11) 4 (-2 to 9) 
Odynophagia 32 (25 to 38) 36 (29 to 43) 5 (-5 to 14) 
Anxiety health in future  61 (54 to 68) 53 (46 to 61) -8 (-18 to 2) 
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Table 15. Mean differences (MD), 95% confidence intervals (ci) and p-value for all patients who completed 
the European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 and 
the oesophageal module after neoadjuvant treatment and one, three and five years after surgery compared 
between allocated groups. A negative score indicates better function/worse symptoms among patients treated 
with nCT and a positive score indicates better function/worse symptoms among patients treated with nCRT   
 
 
 
 
 
 
 
 
Values in bold are both clinically relevant and statistically significant. 
Abbreviations: nCT = neoadjuvant chemotherapy and nCRT= neoadjuvant chemoradiotherapy. Clinical and 
statistical significance are assumed as MD over 10 and p-value <0.05. Longitudinal linear mixed effect 
models with the time interaction term was used to compare HRQoL between the treatment arms at each 
timepoint 
 
 
 
 
 
 
 
 
 
 
Table 15 
After 
neoadjuvant 
treatment 
 1 year after 
surgery 
 3 years after 
surgery  
5 years after 
surgery 
 
QLQ-C30 
MD (95% ci) 
n (112) 
p-
value 
MD (95% ci) 
n (68) 
p-
value 
MD (95% ci) 
n (63) 
p- 
value 
MD (95% ci) 
n (44) 
p- 
value 
Global health/QoL 1 (-7 to 10) - -6 (-16 to 5) - -2 (-13 to 9) - - 8(-23 to 7) - 
Function         
Physical functioning 0 (-7 to 6) - 4 (-4 to 13) - -6 (-15 to 2) - -4 (-16 to 8) - 
Role functioning -3 (-14 to 9) - -1 (-16 to 14) - -9 (-25 to 6) - -12 (-33 to 9) 0.273 
Emotional functioning 8 (0 to 16) - -6 (-17 to 4) - -6 (-16 to 5) - -8 (-22 to 7) - 
Cognitive functioning 4 (-3 to 11) - -3 (-12 to 6) - 0 (-10 to 9) - -6 (-19 to 7) - 
Social functioning -3 (13 to 7) - 0 (-13 to 13) - -10 (-23 to 4) 0.159 -11 (-29 to 7) 0.246 
Symptoms         
Fatigue -3 (-12 to 6) - 2 (-10 to 14) - 9 (-3 to 21) - 10 (-7 to 26) 0.244 
Nausea and vomiting 2 (-6 to 9) - 0 (-10 to 9) - 5 (-5 to 15) - 4 (-10 to 17) - 
Pain -5 (-14 to 5) - -6 (-19 to 6) - 5 (-7 to 18) - -2 (-19 to 15) - 
Dyspnoea 1 (-9 to 10) - 6 (-7 to 18) - 12 (-1 to 27) 0.067 16 (-2 to 34) 0.085 
Insomnia -7 (-18 to 4) - -2 (-16 to 12) - 9 (-5 to 24) - 4 (-16 to 24) - 
Loss of appetite 10 (-3 to 22) 0.121 -7 (-22 to 9) - 5 (-12 to 21) - 5 (-17 to 27) - 
Constipation -4 (-14 to 5) - -6 (-18 to 7) - -2 (-15 to 11) - -2 (-19 to 15) - 
Diarrhoea -3 (-13 to 6) - -9 (-21 to 3) - 0 (-12 to 13) - 6 (-11 to 22) - 
Financial difficulty 3 (-6 to 13) - 5 (-8 to 17) - 6 (-7 to 19) - 8 (-10 to 25) - 
QLQ-OES24/OG25         
Dysphagia 7 (-3 to 17) - -8 (-22 to 5) - -4 (-18 to 10) - -7 (-26 to 11) - 
Eating 5 (-5 to 15) - -1 (-14 to 12) - -1 (-14 to 13) - 3 (-15 to 20) - 
Reflux 4 (-4 to 12) - -7 (-14 to 8) - -2 (-14 to 10) - 2 (-13 to 17) - 
Trouble swallowing saliva -2 (-12 to 8) - -4 (-17 to 9) - -1 (-15 to 12) - 13 (-5 to 30) 0.165 
Choking -7 (-16 to 2) - -4 (-15 to 8) - -6 (-18 to 7) - 2 (-14 to 18) - 
Dry mouth -8 (-19 to 2) - 11 (-3 to 25) 0.123 5 (-10 to 20) - 18 (-2 to 37) 0.075 
Trouble with taste -1 (-10 to 9) - -4 (-17 to 9) - 4 (-9 to 18) - 10 (-8 to 27) 0.271 
Trouble with coughing 7 (-2 to 16) - 5 (-7 to 18) - 17 (4 to 30) 0.011 4 (-13 to 21) - 
Trouble talking 2 (-4 to 9) - 0 (-8 to 8) - -1 (-10 to 8) - 0 (-12 to 12) - 
Odynophagia 11 (0 to 22) 0.047 -5 (-19 to 10) - 0 (-15 to 15) - 4 (-16 to 24) - 
Anxiety health in future  -9 (-22 to 4) - 3 (-13 to 18) - 10 (-7 to 26) - 6 (-16 to 28) - 
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Function/symptom worse compared with baseline (before treatment) 
Function/symptom better compared with baseline (before treatment) 
 
  53 
 
 
 
Function/symptom worse compared with baseline (before treatment) 
Function/symptom better compared with baseline (before treatment) 
 
Figure 2. Health-related-quality of life comparing changes after neoadjuvant treatment (a), one (b), three (c) and five (d) years with baseline in 
each arm and each timepoint using linear regression and mean changes described with waterfall plots  
= (p-value<0.05 and 95% confidence interval ≠ 0). The dashed vertical line at ± 10 indicates the prespecified level for clinically 
meaningful change from baseline. 
Abbreviations: nCT=neoadjuvant chemotherapy, nCRT=neoadjuvant chemoradiotherap 
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6 DISCUSSION 
6.1 METHODOLOGICAL DISCUSSION 
6.1.1 Study design  
There are methodological aspects that needed to be considered in this thesis, which reports 
four papers using three different designs. The field of public health includes epidemiology 
with the study of the occurrence of illness. Studies of illnesses within epidemiology are 
often conducted using cohorts studies, with the broad definition of  “ any designated group 
of individuals who are followed of traced over a period of time” 192,193 and are therefore 
considered to be an archetype of studies within epidemiology. In research, different designs 
can be used depending on the research question and the hypothesis of the outcome 
investigated. When comparing outcomes with an experimental design, for example, using 
randomisation of the defined interventions, the main types are clinical trials, in which the 
investigated subject is diagnosed with a specific disease, although the disease is not the 
event being studied. Clinical trials are considered to be closed cohort studies192 and 
regarded as the gold standard when comparing interventions.  
 A clinical trial needs a well-defined study protocol, containing well-defined exclusion and 
inclusion criteria’s to detect whether one treatment is superior or inferior to the other. To 
gather high credibility, it is also considered important with a multicentre design although 
multicenter randomised controlled trials are time-consuming and expensive, and follows 
strict rules in order to guarantee the safety of the patients being investigated. In clinical 
trials, survival or disease-free survival is often investigated and, with these primary 
endpoints, there is a need for a high number of subjects to be randomised. Instead, with rare 
diseases it is possible to use surrogate variables as histological responses or other defined 
treatment responses as primary outcomes, as used in the NeoRes trial. Nowadays, it is also 
common to use HRQoL as primary outcomes within trials. Additionally, it is considered a 
golden rule to analyse the primary outcomes of randomised clinical trials using intention to 
treat analysis, since it is debated whether per protocol analysis is truthful. In this thesis, 
papers (II), III and IV is reporting data from the randomised NeoRes trial.  
Nationwide cohort studies are a necessary balance for the outcomes of randomised trials. 
Nationwide data collection that is often initiated by governments in order to gain statistics 
of health outcomes in countries – which in Sweden is conducted via national registries – 
does not consume as many resources as randomised controlled trials. The Nordic countries 
have a history of registries within several areas, thus a structure exists. The superiority of 
using nationwide registries, also called “open cohort studies”192, is that of they provide a 
real-world picture of all patients within the field being investigated. In this thesis, Paper I 
examines data from a nationwide population-based registry cohort.  
Beyond, randomised trials or a nationwide registry are several prospective and retrospective 
designs when new hypotheses, treatments, outcomes etc. are being tested, as well as a use 
of a more detailed understanding with both quantitative and qualitative research outcomes. 
In this thesis, we present studies designed as prospectively collected data from a single 
centre cohort study in Paper II to a multicentre phase II, open, randomised controlled trial 
involving patients with oesophageal cancer in surgical and oncological centres in Sweden 
and Norway in 2006 to randomisation ending in 2013 and conclusion of a five-year follow-
up in 2018. Paper I involve prospectively collected nation-wide registry data from NREV. 
The data have been collected from 2006 and is ongoing. This paper presents patient- 
reported outcomes in patients diagnosed between 2009 and 2016. 
Other designs considered are case-control studies. This design investigates subjects who 
have a disease and may also be matched with subjects without a disease as a reference 
group. Often, the relationship of a suspected risk factor or an attribute of the disease is 
examined by comparison of diseased and non-diseased groups. This is usually called a 
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retrospective design, because it investigates the onset of the disease and backwards to the 
causal factors. Nowadays, cases and controls are collected prospectively, with meaning that 
collection of data starts before any cases have been diagnosed.  
 
6.1.2 Validity 
Two main sources of error in quantitative research needs to be considered. One is the 
systematic error, often referred to as bias, and this may affect the validity of the results. 
Second, is the random error affecting the precision of the results. The validity of the 
findings in research is named internal validity and it depends on the level of systematic 
error. When performing studies efforts are to minimize biases.  
 
Validity is considered to be the relative absence of bias or systematic errors, and expresses 
of the degree to which a measurement measures what it is intended to measure, called 
construct validity. Furthermore, content validity concerns the content for which the 
measurement incorporates the domain of the phenomena of the study. Lastly, criterion 
validity, measures the extent to which the measurement correlates with an external criterion 
of the phenomenon being studied. There are two aspects of criterion validity to be 
considered: firstly, concurrent validity, meaning that the measurement and other criterion 
refer to the same point in time. Secondly, predictive validity, meaning that the 
measurement’s validity is expressed in terms of its ability to predict the criterion. In this 
thesis, the validity of the outcomes is considered strong regarding Papers I, III and IV 
because these instruments have been tested and retested within several settings. Paper II 
used other measurements to evaluate dysphagia. The instruments have previously been used 
within other settings and in clinics but both measurements using Ogilvie score and Watson 
scale have recently been validated and published confirming its validity in Swedish 
settings. However, when comparing between instruments, the EORTC oesophageal 
instrument QLQ-OG25 was considered better at evaluating dysphagia compared to Watson 
and Ogilvie.175 To enhance validity, in Paper I we adjusted for potential known confounders 
while in Papers III and IV, because of the randomised design, we suggested that validity 
was high because of the multicentre design, the randomisation and the stratification of 
histology.  
6.1.3 Bias in design 
A bias is a systematic error introduced at any stage that may interfere with the results. 
Selection bias is important to consider in the design of trials with properly inclusion and 
exclusion criteria. Such bias may be reduced through rigorous criteria to avoid confounding 
the results. During the trial there were several other biases to consider that could impact the 
outcome, such as performance bias and misclassifications. Papers III and IV may be biased 
due to missing data collection of HRQoL questionnaires. However, by use of well validated 
instruments we may have reduced misclassification for HRQoL outcomes.  
Misclassification is a type of systematic error and is also defined as an information bias. 
There are two types of misclassification. Differential misclassification may both 
overestimate or underestimate the true value. In differential misclassification, the errors are 
related to either exposure or outcome. In non-differential misclassification, the errors are 
related to both exposure and outcome. In Paper II the patients reported dysphagia and 
appetite via phone or at meetings and the interviewer recorded the answers. It is important 
to consider interviewer bias regarding how information is solicited, recorded and 
interpreted, together with the knowledge of the interviewers. 
 
Attrition bias is incomplete outcome data and is especially important to consider in clinical 
trials reporting HRQoL. The missingness of data is the source of trustworthiness of the 
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results. Paper III and IV report the outcomes of NeoRes trial, and data is missing. Also, an 
important consideration is why the HRQoL follow-ups have been missed, although this was 
not recorded in the trial. Trials with significant PRO differences between arms, had greater 
completeness of reporting. This requires future attention.113  Also, with a low rate of 
collected HRQoL questionnaires in Paper I, attrition bias is important to consider.  
6.1.4 Random errors 
Random errors are described as the variability or degree of precision of any measurement 
related to sample size, often described in statistics as type I and type II errors. The outcome 
of a statistical test is a decision to either accept or reject the null hypothesis (H0) in favour 
of an alternative hypothesis (H1). It is never possible to know the truth, but an objective 
truth is measured. Type I error or alpha error is an incorrect rejection. For example, if a 
95% confidence is claimed, then there is a 5% probability, if there is no bias or incorrect 
assumption, to make a wrong assumption about your tested hypothesis. If the test 
hypothesis is false but is not rejected, the incorrect decision not to reject is called a type II 
error, or beta error. Thus, it is important to consider the power, by considering the alpha 
level and the actual magnitude of the population, relative to the amount of noise in your 
data called effect size and, lastly, sample size. In Paper II we have considered the 
possibility of producing a type II error, because of the small sample size. 
  
6.1.5 Reliability  
Reliability or the internal validity refers to the accuracy of the study results. An estimate 
that has little random errors is precise and both precision and validity are components of 
accuracy. The internal validity refers to the subjects inside the population investigated. 
Three violations to internal validity is categorized; namely confounding, selection bias and 
information bias. Furthermore, the reproducibility of a study and tests whether a 
consistency exists to the instruments used to measure the outcome of interest. Reliability of 
research is the agreement of using the same measurement technique and agreement of the 
replicate measurement at different points in time. A reliable test measure something in a 
consistent, repeatable and reproducible manner. In statistical terms the reliability of a scale 
in an instrument is increased by inclusion of and average a number of items, and each item 
is associated with an independent random error term. In HRQoL research, Cronbach’s 
coefficient alpha is a measure of reliability in multi-item scales. There are also ongoing 
discussions regarding whether a single item is reliable.93  
6.1.6 Confounding 
A confounder is a systematic error, and may interfere with both the exposure and the 
outcome, making it difficult to know what is being measured. Often described as a  
” confusion of effects” and it leads to a bias. This may be controlled at analysis or by 
restriction.  The confounder is related to exposure and outcome, and is not an intermediate 
in the causal pathway from exposure to outcome. To minimise confounding, randomisation, 
restriction or matching is used. Papers III and IV in this thesis reports the secondary 
outcomes of a randomised controlled trial, while Paper I comprises data from a population-
based register NREV. Here it is important to consider confounding, and a method to reduce 
confounders is to adjust for potential confounders using multivariate regression. Residual 
confounding is a misclassification of confounding variables, unknown confounders or 
adjustment in categories that are too wide. Confounding by indication is confounding that 
leads to a distorted estimate of the association between the uses of a drug (or class of drug). 
This is preferentially prescribed to subjects who have, a priori- a higher or lower risk of 
presenting the event, especially considered in observational studies. Unlike bias, which is 
primarily introduced by the investigator or study participants, there are two ways of dealing 
  57 
with confounding in the analysis of data: stratification or the use of regression models. In 
Paper II confounding needs to be considered, because some patients needed support of 
parenteral nutrition, and this may to some extent confound the interpretation of weight-
stability.  
 
6.1.7 Generalisability 
Generalisability, also named “external validity”, is a measure of how well results may be 
applied to a larger population or similar others. An important consideration of external 
validity is whether your data have missingness at any stage of your research. This is 
important to consider in this thesis as both Papers I and IV report HRQoL in both a 
population-based study and in a randomised controlled trial. The, amount of missing 
HRQoL instruments, may question the external validity. The conclusions drawn may be 
carefully interpreted suggesting more knowledge needed in the field.   
6.1.8 Interpretation of HRQoL scores 
The instrument EORTC QLQ-C30, was adopted in Papers I and IV, while the oesophageal 
module QLQ-OG25 was added in Paper I. In addition, the oesophageal-specific modules 
QLQ-OES24 and QLQ-OG25 were adopted in Paper IV, and in Paper III the dysphagia 
scale in the oesophageal module was used. All items have a 4-point Likert scale from (1) 
“not at all”, (2) “a little”, (3) “quite a bit”, and (4) “very much”, with the exception of the 
global health/QoL scale having a seven-point scale ranging from (1) “very poor” to (7) 
“excellent”. The assessment provides information about the multidimension scale global 
health/QoL, functions and symptoms related to the treatment and known oesophageal- 
specific symptoms. The responders are asked to provide a summarized information of 
experience over the last week. Raw scores from the responses are calculated and 
transformed into a scale of 0–100 points according to instructions from the EORTC scoring 
manual.191 A higher score on the global health/QoL and functional scales indicated better 
function while on a symptom scale or a single item a higher score means worse symptoms.  
 
When adapting information from HRQoL outcomes, it is important to consider whether 
baseline information is provided from a healthy reference population or baseline score from 
randomised controlled trials. The interpretation is very different. In population-based 
research, the recommendation is to provide information before the subject becomes ill 
Thus, a reference population of a general population is often adapted as a baseline 
comparison.194 In trials, it is important to consider the subjects scores at baseline, to enable 
true subjective differences and changes of treatment over time.93,195 
 
In HRQoL research, the clinically meaningful difference is important to consider and there 
is still a need for a clear method for determining the clinical meaningfulness of changes in 
scores and not only adopt statistical significance. This is especially useful when working 
with large datasets, in which a statistical significance is likely to be obtained.196 The 
methodology of clinical significance is moving forwards, with the adaption of minimally 
important differences. However, discussion are ongoing regarding how much change is 
clinically important.138 A guideline that analyses and interprets PRO data proposes that a 
change of 10 on a 0–100 scale is supported of clinical meaning.190,197 It is said to be of the 
same magnitude as 0.5 standard deviation (SD) and is universally acceptable.198 However, 
in some instruments, a lower SD may be more accurate. The magnitude of clinical 
significance may currently have to be determined on an each trial base, although with 
increased knowledge of HRQoL in trials, clinicians will gain more insight into the 
magnitude of change that is clinically important.138 
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In this thesis, two different approaches were used to aid the interpretation of clinically 
meaningful differences. In the first Paper, we both adopted the recently published paper 
from Cocks et al.189  for EORTC QLQ-C30, while in the analysis of QLQ-OG25, we used 
the hitherto most commonly adapted method, by Osoba and Kings, their interpretation with 
a difference of 10 or more of being moderate clinically meaningful.116,190 Cocks et al. used 
a meta-analysis approach and blinded expert opinions to suggest clinically relevant changes 
within each subscale of QLQ-C30. In Papers II and IV, we used the interpretation of 10 as 
being clinically meaningful. The interpretation of HRQoL in this thesis is considered from 
an anchor-based approach and does not use the effect size interpretation.  
6.2 DISCUSSION 
6.2.1 Paper I 
The main findings in this paper comparing HRQoL within a Swedish population-based 
cohort one year after diagnosis of oesophageal or GOJ cancer, generally low global 
health/QoL, deteriorated functions and more symptoms were reported, especially in 
comparison with the gender and age matched reference population. Patients managed with 
palliative treatment intention reported, as expected, lower function scores and higher 
symptom scores compared to those with intended curative management. With more 
pronounced differences regarding physical function, dysphagia, anxiety of future health, 
problems eating with others and trouble with taste. In addition, within the curative cohort, 
patients treated with dCRT reported more problems with dysphagia, eating problems and 
choking compared to the curative surgical cohort. Conversely, subjects treated with surgical 
resection reported more problems with diarrhoea compared to those treated with dCRT. 
High levels of anxiety for future health and low general health/QoL scores were reported in 
total in the cohort compared to the reference population.  
 
Considerations of methodology needs to be discussed, it is a strength to report nation-wide 
prospectively collected HRQoL within a population-based registry. This limits selection 
and recall-bias, also reflect a true unselected population with a more reliable representation 
in decision-making. The use of globally validated instruments strengthens the outcomes. 
However, limitations need to be considered, and especially collection of HRQoL data at 
only one time-point it is not possible to report changes over time. In addition, the definition 
of the sub-cohort is based on treatment decision at MDT one year earlier, and this may not 
reflect the true given treatment and especially among subjects with curative treatment that 
during the first year may have recurrence and therefore treated as palliative at the timepoint 
of data collection. Missingness of data is considerable and this may further limit 
interpretation of data. The missingness of formulas are probably lower than reported, 
mainly because some regional cancer centres did not collect PRO outcomes during the first 
years of HRQoL in NREV. Also, data from some subjects may have been reported into the 
register later than one year after diagnosis. This will probably further affect the response 
rates of PROM data collection.   
 
When reporting HRQoL outcomes it is important to consider that the responders have 
probably gone through personal changes during treatment and time, and especially one year 
after diagnosis all subjects have to some extent changed their personal values, internal 
standards or meaning of HRQoL. This is named response shift, 67,126 and important in 
interpretation of HRQoL outcomes, especially by use of guidelines when interpreting 
clinical relevance. In this paper we considered that response shift was similar in all 
subgroups. 
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The findings of this paper suggest improvements and especially need of more psychological 
support because of the high levels of anxiety reported one year after diagnosis among both 
curative and palliative subjects. Distress and anxiety have previously been highlighted in 
oesophageal cancer and other cancer diagnoses as an important symptom to be aware of. 
153,199  Identifying distress and anxiety is recognised as a sixth vital sign in cancer care, and 
needs to be monitored routinely, to identify individuals experiencing high levels of anxiety 
and distress as a significant burden.199 It has earlier been recognised that patients one year 
after diagnosis within several cancer diagnosis report high levels of distress.133,199 
 
In addition, the oesophageal problems, particularly problems with dysphagia, have been 
found to be a causative distressing factor among surgically treated subjects with 
oesophageal cancer, and this may also be considerable in palliative settings.153 One earlier 
paper have also addressed that dysphagia, uncertainty and fatigue influenced the subject’s 
everyday life and that need of support and information is important.182 Therefore, to 
investigate the underlying causes of why patients report problems of dysphagia one year 
after diagnosis in palliative subjects and those treated with dCRT is crucial. To decrease 
dysphagia is one of the main objectives in palliative treatment. It has earlier been addressed 
that dysphagia may recurrence with treatment with stents 142,162 and in comparison between 
palliative modalities it is also known that treatment of brachytherapy is considered with 
longer relief of dysphagia compared to stenting.143 Also, treatment of dysphagia it is 
common with stenting in palliative patients and when treated with dCRT insertion of PEG 
to secure nutrition are widely used, thus not actually addressing swallowing ability. 
Although, deeper knowledge of the management of dysphagia is not available in this study.   
 
The problem of diarrhoea is a well-known side-effect that is reported after oesophageal 
cancer surgery, probably to a large extent influenced by the vagotomy usually performed as 
an inherent part of the dissection.47,129,137 Currently, early tumours with T0-T1 stage is 
mostly offered only endoscopic treatment, while in the beginning of this study cohort a 
large proportion were treated with oesophagectomy.   
 
It is important to focus on the care that is needed to return persons to their fullest possible 
function in society after a cancer diagnosis. Both curative survivorship and palliative care 
require a holistic approach in order to address the physical, emotional, and social needs of 
patients with oesophageal cancer. This is an essential component of care from the time of 
diagnosis and throughout the person’s life.39,40,200 
6.2.2 Paper II 
The main findings of this prospective cohort pilot study were that treatment with platin-5-
Fluorouracil chemotherapy with or without the addition of radiotherapy, significantly 
reduces dysphagia, in patients diagnosed with locally advanced oesophageal or GOJ 
carcinoma. The relief was clearly significant already after the completion of first treatment 
with neoadjuvant chemotherapy with platins. In addition, no correlation was detected 
between the alleviation of dysphagia and histological response. 
 
The main weakness of this paper is the small sample and that data was collected only at one 
centre, at Karolinska University Hospital. This study may introduce type II error, but since 
the findings were so clear we consider this to not fully explain our findings. A strength of 
this study is the use of PRO to assess dysphagia and also the main outcomes were 
prospectively collected.  
 
Two previous reported papers have investigated HRQoL during neoadjuvant treatment, the 
first paper reported relief of dysphagia after two cycles of chemotherapy 172 and the second 
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paper reported stable dysphagia or relief of dysphagia after ended neoadjuvant treatment 
before surgery.126  Although, these papers have not reported any intervention with stenting 
or other possible procedures to relive or support dysphagia, therefore a chance of bias may 
be considered in those papers. Recently also Cools-Lartigue et al, also explored dysphagia 
during neoadjuvant therapy in and investigating whether invasive tube placement either 
surgically or radiographically could be avoided, since it causes significant morbidity. 
Treatment given in this study was three- or four modalities of chemotherapy. Patients with 
dysphagia over 2 with at least 10% weight loss, received a fast track with start of first cycle 
of chemotherapy one week of presentation. Their findings suggested that patients 
experienced sufficient relief of dysphagia permitting the patients to start eating adequately 
and patients remained weight stable, after completion of several chemotherapy modalities 
containing platins.171 In addition, within palliative treatment also relief of dysphagia have 
been described with chemotherapy of platins and 5-FU and addition of radiotherapy. 74 
 
In this paper we did not note that any patients receiving addition of radiotherapy reported 
deterioration of appetite or swallowing discomfort after completion of nCRT. It has been 
reported that amongst 15% –28% of the patients receiving radiotherapy develop radiation-
induced oesophagitis 15. A reason for not reporting this, is that the measurement was before 
surgery approximately 3-6 weeks after completion of nCRT. It is reported that the effect of 
radiotherapy induced oesophagitis, will recover after a few weeks after completion of 
radiotherapy.201  
 
This paper is important in clinical-decision making, with increased knowledge of how 
patients should be managed regarding dysphagia and nutritional considerations at diagnosis, 
during neoadjuvant treatment and until surgery. Moreover, earlier papers have reported that 
neoadjuvant treatment may significantly worsen nutritional parameters compared to 
patients undergoing resection upfront,158,167,202 while other recently published papers report 
that with professional support during neoadjuvant treatment patients may keep weight-
stability and continue oral intake without stent or gastrostomy placement.163,171 Stenting is 
also reported having a negative outcome impact on oncology.159 
6.2.3 Paper III 
The main findings of patient-reported dysphagia in the NeoRes trial comparing baseline 
and at completion of neoadjuvant treatment, was firstly that patients reported relief of 
dysphagia with improved ability to eat solid food in both groups. Secondly, radiotherapy 
induced oesophagitis may increase symptoms of swallowing problems. Thirdly, no 
correlation was detected between relief of dysphagia and histological tumour response in 
the NeoRes trial.   
 
The weaknesses of this paper are the missing HRQoL formulas at both baseline and after 
neoadjuvant treatment, this reduces the power of secondary endpoint observations and also 
possibly introduce a risk of selection bias. Also, the lack of timing when questionnaires 
were returned after neoadjuvant treatment will probably influence the results. Another 
consideration is that it is not recommended to only analyse single scales and not reporting 
the other outcomes collected. However, the individual items and the scale added important 
information in this paper as the subanalysis of each separate item enabled us to better 
understand the degree of swallowing problems and to which degree relief of dysphagia was 
improved by neoadjuvant treatment. The major strength, is the randomised procedure with 
similar groups and with inclusion criteria’s, enabling true comparisons between groups. 
 
Previous literature supports the findings with relief of dysphagia during neoadjuvant 
therapy.171,203 172  In addition, the management of nutrition in oesophageal cancer, 
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especially when patients also suffer from dysphagia, is a challenge during and after 
completion of neoadjuvant therapy. At diagnosis, dysphagia with associated weight loss 
and malnutrition is the main clinical manifestation of oesophageal cancer and in order to 
tolerate curative treatment it is important to succeed in the management of symptoms at 
diagnosis and during neoadjuvant treatment.167,171 178,204  
One side-effect reported is radiotherapy induced oesophagitis, which is associated with 
increased dysphagia and odynophagia.15,158,201 The dynamics of oesophagitis are not well 
documented, but it is reported to peak approximately three to five weeks into treatment and, 
in some patients it may take several weeks after termination before it resolves.204 To assess 
symptoms and the effectiveness of symptom management strategies, patient-reported 
outcomes are an important component in combination with the clinical judgement.  
 
The lack of correlation between relief of dysphagia and pathohistological tumour response 
has been well-described in previous literature. 172,187,201,203,205 However, the findings of an 
increased ability to eat solid food should be explained by the debulking effect of tumour 
being enhanced by neoadjuvant treatment. Why this effect cannot explain the tumour 
response is unresolved.  
 
Since 2010, by law (Patient law 2014:281), all cancer patients in Sweden shall be offered a 
contact nurse. This is to enhance information, improve communication with health-care, 
increase safety, continuity and patient-centeredness during treatment trajectory. This further 
increase safety when patients is introduced to new treatment strategies and the patients need 
for specialised support at diagnosis, during treatment and long-term follow up after ended 
treatment is addressed in several papers in oesophageal cancer. 85,86,181,184,186   
 
 
6.2.4 Paper IV 
The main findings in this paper reporting patient-reported HRQoL outcomes in the NeoRes 
trial, was that in comparison between treatment groups patients reported clinically relevant 
and statistically significantly more problem with odynophagia after completion of nCRT 
compared to those who received nCT. Also, at three years follow-up after surgery patients 
allocated to nCRT reported clinically relevantly and statistically significantly more 
problems with coughing, compared to those treated with nCT. In longitudinal analysis 
within treatment allocation and in comparison, with baseline, the overall finding was that 
patients treated with nCRT reported more symptoms, lower global health/QoL and 
functions after completion of neoadjuvant treatment. In addition, at five years follow-up 
after surgery patients reported worsen problems with reflux and dyspnoea when treated 
with nCRT in comparison with nCT. However, some oesophageal symptoms improved, 
especially after completion of neoadjuvant treatment but also over time, and this was 
reported in both arms.  
 
Methodological considerations to be discussed is the major strength of HRQoL analysis of 
randomised multicenter trial comparing neoadjuvant treatments and surgery in oesophageal 
cancer. A randomised comparison provides the best validity in comparison between 
treatments. Also, the use of globally validated HRQoL instruments is considered a strength, 
especially when validated to compare oncological and surgical settings in cancer and 
oesophageal cancer treatment. A limitation is the multi-testing of all HRQoL outcomes, 
with no specific primary or secondary outcome predefined. Another limitation is the lack of 
reporting the reason for and the number of missing HRQoL questionnaires particularly 
during follow-up. However, no difference was found when responders and non-responders 
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were compared. Also, the criteria of patients included with WHO score 0-1 limit the 
generalizability.   
 
This is the first trial reporting HRQoL comparing nCRT and nCRT in oesophageal and 
GOJ carcinoma before surgery. Therefore, our findings are novel contribution within the 
area, but it is known that neoadjuvant therapies are followed by deterioration of several 
symptoms and functions especially shortly after completion of neoadjuvant therapies.  
In addition, it is acknowledged that oesophageal cancer surgery is associated with short- 
and long-term deterioration of HRQoL.61,121,126,129,137 Many studies have reported huge 
detrimental effect of surgery but with partially recovery over time, although some functions 
impaired and symptoms never recovered or being chronic.63,69,71,121 Also, outcomes from 
population based studies reported HRQoL and compared with a reference population, they 
reported no recovery after oesophageal cancer surgery at 6 months, 3 years and up to 10 
years in several aspects. 47,62,121,130 Our findings are in line with other studies, reporting a 
detrimental effect of HRQoL outcomes after completion of neoadjuvant treatment, but we 
also detected improvement especially in some oesophageal reported symptoms.  
 
One observational study has reported outcomes comparing neoadjuvant chemotherapy and 
neoadjuvant chemoradiotherapy before surgery and the authors reported detrimental effect 
during neoadjuvant treatment with both nCT and nCRT, but before surgery HRQoL 
recovered to baseline levels. Also, after surgery the same study concluded that neoadjuvant 
treatment did not hamper HRQoL outcomes compared to surgery alone and patients 
recovered in six months after surgery to baseline measurements.126  
 
In addition, the CROSS trial comparing nCRT and surgery alone, reported deterioration in 
all aspects of HRQoL one week after termination of nCRT while at follow-up during the 
first year and a long-term follow-up at eight to nine years after surgery, they reported no 
difference in HRQoL outcomes when comparing surgery alone and nCRT + surgery. 
Although, physical function and fatigue was impaired at one year and in the long-term 
follow-up after surgery and they never restored to baseline levels in any of the allocated 
groups.69,71 Our results in the NeoRes trial, detected that physical function was significantly 
impaired after neoadjuvant treatment in the nCRT group, while at one year follow-up after 
surgery physical function worsen in both allocated groups, although at three years follow-
up changes were only detected among patients treated with nCRT.  
 
In comparison with a Swedish reference population at six months and three years after 
surgery, functions deteriorated (role and social) and several problems with symptoms were 
reported (fatigue, appetite loss, diarrhoea, dyspnoea and reflux).47,129 Long-lasting 
deterioration in social functioning, fatigue and coughing have also earlier been reported in a 
meta-analysis comparing HRQoL up to one year after surgery.137 In the NeoRes trial, 
fatigue is only reported with significant results after completion of neoadjuvant therapy in 
both groups and also in comparison between groups at five years follow-up fatigue were to 
some extent more severe among patients treated with nCRT compared to nCT. Patients 
reported that role and social function, were also to some extent worsen when treated with 
nCRT at long-term follow-up compared to nCT. In addition, problem with dyspnoea and 
coughing were worsened when treated with nCRT at long-term follow-up compared to 
nCT. This is also detected when longitudinally changes from baseline were analysed within 
especially the nCRT group, long-term deterioration of dyspnoea were reported and problem 
with coughing at three years follow-up. Reflux were impaired at three years follow up in 
both groups and at five years follow-up only in the nCRT group. Loss of appetite were 
improved or stable compared with baseline and over time in both groups while diarrhoea 
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were reported with problems at one- and three-years follow-up in respectively nCT and 
nCRT group.  
 
Restoration to baseline level at six months after completion of treatment have also been 
reported in trials comparing dCRT therapies.122,123 Rees et al. reported HRQoL within the 
SCOPE-1 trial comparing dCRT therapies, at follow-up one year and 104 weeks, they 
reported that scores were similar or better than before treatment.123  However, patients 
reported HRQoL outcomes in the NeoRes trial were not restored at one year after surgery 
and differences were detected between treatment allocation in both short and long-term 
follow up. The CROSS trial reported no difference over time between nCRT plus surgery 
and surgery alone, an explanation may be the different methodology adapted in analysis of 
the results, with use of multiple corrections in the CROSS trial.  
 
The different methods adapted in interpretation of HRQoL results within trials, have 
recently been discussed. A review was published on advanced breast cancer describing 
standards and quality of reporting outcomes from randomised trials.206 This review looked 
at statistical issues and considerations. Their conclusion was that the reporting of the 
outcomes of trials did require consensus because of a wide spread of reporting and 
consequently complicate the interpretation of PRO. Although, most of the trials have 
baseline data, and linear mixed effect models was the most used statistical model together 
with ANOVA/Linear regression and Wilcoxon and T-tests in comparison between patient 
groups. 
 
The implication of HRQoL outcomes in the NeoRes trial with report of more symptoms 
especially over time in the nCRT group, needs to be confirmed in larger trials. Earlier 
results in the NeoRes trial have though reported more severe complications after surgery 
with nCRT treatment 41 and no survival benefit of either treatment is reported.18 The 
NeoRes trial do not have statistical power to compare long-term outcomes, but it is the 
largest trial hitherto comparing nCRT and nCT with surgery.  
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7 CONCLUSIONS 
• The overall HRQoL in patients with oesophageal cancer one year after diagnosis is much 
lower in comparison with an age and gender matched reference group from the general 
population. 
• Anxiety is a major concern for oesophageal cancer patients one year after diagnosis. 
• Patients with up-front palliative treatment intent, and patients recommended to receive  
dCRT at MDT, report high scores for dysphagia and other eating related symptoms, one 
year after diagnosis. 
• Diarrhoea is a significant symptom one year after diagnosis in patients treated with 
curative intent surgery. 
• During neoadjuvant treatment patients reported relief of dysphagia already after the first 
cycle of chemotherapy, followed by further relief after completed neoadjuvant treatment. 
• In comparisons between nCT and nCRT, relief of dysphagia and improved ability to eat 
was experienced after both treatments, although patients initially without dysphagia who 
received nCRT reported some deterioration of eating ability after treatment, possibly due 
to radiation therapy-induced oesophagitis. 
• No correlation was detected between dysphagia response and histological tumour 
response after neoadjuvant therapy. 
• Only minor HRQoL differences were detected in the direct comparison between patients 
treated with nCT and nCRT, with less odynophagia immediately after completed nCT 
and more problems with cough and dyspnoea at long term follow-up after nCRT.  
• In longitudinal, long-term analyses, patients reported severe deterioration of HRQoL after 
surgery both after nCT and nCRT, with gradual long-term recovery after both treatment 
types, but with more long-term symptoms remaining, compared to baseline, in patients 
treated with nCRT. 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Cancer i matstrupen (esofagus) är en tumörsjukdom med relativt dålig prognos jämfört med 
andra cancerdiagnoser, men prognosen har förbättrats det senaste decenniet med 
kombinerade behandlingar, som inkluderar framsteg inom onkologi och kirurgi. I Sverige, 
diagnosticeras cirka 450–500 personer årligen med esofaguscancer och sjukdomen är 
vanligast förekommande hos män. Två huvudtyper dominerar, körtelcancer 
(adenocarcinom) och skivepitelcancer. Kända riskfaktorer för adenocarcinom är rökning, 
övervikt och halsbränna och för skivepitelcancer är de dominerande orsakerna rökning och 
alkohol. Sväljsvårigheter, även kallad dysfagi är kardinal symptomet för 70%-90% av 
individerna vid diagnos, men på grund av matstrupens elasticitet uppkommer inte 
symptomet innan tumören har växt så att 75% av matstrupens lumen är täckt av tumören, 
därav en avancerad sjukdom vid diagnos.  
 
En viktig del av forskningen idag är fokuserad på överlevnad, biverkningar, komplikationer 
och respons på behandling, men de senaste decennierna så har även personers subjektiva 
rapportering (PRO) om den egna hälsan med rapportering om livskvalitet, 
funktionsförmåga, samt symptom av sjukdomen eller behandlingen, blivit viktiga att 
undersöka. Syftet med denna avhandling är att utvärdera person rapporterad hälsorelaterad 
livskvalitet och dysfagi hos patienter som har diagnosticeras med cancer i esofagus. 
 
Vid diagnos av esofaguscancer så finns flera behandlingsalternativ att tillgå, beroende på 
tumörstadium och individens hälsa. Vid botande behandling, så är i dagsläget förbehandling 
(neoadjuvant) med kemoterapi eller kemoradioterapi innan kirurgi vanligast. Kirurgisk 
behandling räknas idag som den enda botbara behandlingen. Studier pågår dock för att 
undersöka om definitiv kemoradioterapi kan vara botande behandling framförallt för 
personer diagnosticerade med skivepitelcancer i esofagus. Med neoadjuvant behandling har 
det påvisats att tumörbördan minskas och även minskad risk för spridning till lymfkörtlar, 
dock med ökad risk för toxiska symptom och komplikationer vid kirurgi. På grund av de 
sena symptomen vid diagnos är 70% av individerna palliativa redan vid diagnos, och om 
möjligt ges då onkologisk behandling för att främst lindra symptom och förlänga 
överlevnad.  
 
Fyra delarbeten ingår i avhandlingen, två arbeten presenterar personrapporterad HRQoL 
och två arbeten utvärderar sväljförmåga under, före och efter onkologi. Tre av arbetena II 
(delvis), III och IV är delarbeten i en randomiserad kontrollerad studie, utfört mellan 2006 
och 2013 i Sverige och Norge. NeoRes som studien kallas, inkluderade 181 personer som 
randomiserades mellan neoadjuvant kemoterapi eller neoadjuvant kemoradioterapi före 
kirurgi. HRQoL samlades in före, under behandling och upp till fem år efter kirurgi. För att 
utvärdera behandling är den bästa metoden att jämföra inom en randomiserad kontrollerad 
studie, dock är det viktigt att konkludera de uppnådda resultaten med data från nationella 
kvalitetsregister då det kan spegla en sannare bild av populationen jämfört med 
randomiserade studier.  
 
Arbete I är en sammanställning av HRQoL formulär som har registrerats i det nationella 
kvalitetsregistret för esofaguscancer och ventrikelcancer (NREV). Totalt inkluderades 1156 
personer med esofaguscancer som har registrerats mellan 2009 till 2016 och som har fått 
hemskickat frågeformulären ett år efter diagnos. Syftet var att beskriva HRQoL på alla 
individer som har blivit registrerade i NREV och jämföra med en ålders- och könsjusterad 
referenspopulation, samt att analysera HRQoL mellan den palliativa och kurativa kohorten 
och inom varje subkohort. Huvudresultaten visar att i jämförelse med referenspopulationen 
så rapporterade personerna med både kurativ och palliativ diagnos, lägre global 
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hälsa/livskvalitet, lägre funktioner och mer symptom ett år efter diagnos. Analyser mellan 
individer som har fått palliativ diagnos och de som har fått kurativt syftande behandling 
visade att HRQoL är sämre hos gruppen som har fått palliativa diagnos, framförallt sämre 
fysisk förmåga och mer sväljsvårigheter rapporterades. I tillägg så rapporterade de individer 
som fått enbart kemoradioterapi mer sväljsvårigheter jämfört med de kurativa kirurgiska 
kohorterna, medan kohorterna som har genomgått kirurgi rapporterar mer problem med 
diarré. Mycket symptom på ångest för den framtida hälsan och lågt skattad global 
hälsa/livskvalitet rapporterades i hela NREV kohorten.  
 
Arbete II är en kohortstudie på patienter som har behandlats på Karolinska 
Universitetssjukhuset. Syftet var att undersöka dysfagi före behandling, under neoadjuvant 
behandling och före kirurgi. Resultaten visade att dysfagi efter första kur med cytostatika 
minskade så att förmågan att äta fast föda ökade och sväljsvårigheterna minskade 
ytterligare innan kirurgi. Studien visar att man skall vara ytterst selektiv vid behandling 
med stent eller att sätta gastrostomier på patienter inför neoadjuvant behandling och kirurgi.  
 
I arbete III utvärderades dysfagi med en skala från HRQoL instrumentet. Resultatet visade 
att båda neoadjuvanta behandlingarna i NeoRes minskade dysfagi problemen efter avslutad 
behandling jämfört med innan behandling. Även att vissa patienter troligen får biverkningar 
av strålbehandlingen i form av inflammation i matstrupen (esofagit), som därmed kan 
försämra sväljförmågan under en tid. Inget samband påvisades mellan respons på dysfagi 
och patologisk respons på de givna neoadjuvanta behandlingarna.  
 
I arbete IV analyserades HRQoL i NeoRes där data insamlades före behandling, efter 
neoadjuvant behandling, samt ett, tre och fem år efter kirurgi. Resultaten visade i 
jämförelse mellan behandlingsgrupperna att behandling med kemoradioterapi gav något 
mer signifikant symptombörda jämfört med enbart kemoterapi, med mer smärta vid 
sväljning (odynofagi) efter avslutad neoadjuvant behandling och mer problem med hosta 
vid tre års uppföljning efter kirurgi. Mätningar över tid visade att patienter som har fått 
neoadjuvant kemoradioterapi rapporterade mer symptom med reflux och dyspne vid 
femårsuppföljningen.  
 
Sammanfattningsvis så visar avhandlingen att den rapporterade HRQoL är lägre jämfört 
med en referenspopulation ett år efter diagnos i NREV och det inkluderar lägre global 
hälsa, lägre rapporterad funktionsförmåga och mer symptombörda. Ångest inför den 
framtida hälsan rapporterades i hela kohorten och även problem med dysfagi rapporteras 
hos individer med palliativ behandlings intention och kurativ definitiv kemoradioterapi ett 
år efter diagnos. Vidare så minskar problem med dysfagi med neoadjuvant behandling av 
antingen cytostatika enbart eller i kombination med strålning innan kirurgi och redan efter 
första cytostatika kuren förbättras sväljförmågan så att förmågan att äta fast föda 
förbättrades. Inget samband mellan respons på dysfagi och histologisk respons har kunnat 
påvisas. HRQoL i NeoRes visade att patienter som har fått neoadjuvant kemoradioterapi 
rapporterade en högre signifikant symptombörda jämfört med patienter som enbart har fått 
kemoterapi före kirurgi, med mer rapporterade symptom på odynofagi efter avslutad 
neoadjuvant behandling, och problem med hosta, dyspne och reflux efter kirurgi.  
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9 FUTURE PERSPECTIVES 
 
It is important to improve completion of PRO outcomes. This is needed both in future 
randomised controlled trials and in the national quality registry for oesophageal cancer, 
NREV. A strategy to improve completion of HRQoL questionnaires may be to use modern 
technology and centralization of such data collection in future trials. In NREV, we need to 
improve and investigate how we can improve collection of PRO data.  
 
Dysphagia problems in long term follow-up needs to be addressed, especially among 
subjects diagnosed as palliative and among subjects treated with definitive 
chemoradiotherapy. A deeper knowledge of how palliative and dCRT treatment affect 
dysphagia is important. In addition, it is important to screen symptoms of recurrence or 
early and late side-effects of therapy and also to address the psychological effects enhanced 
by the cancer treatment. High levels of anxiety of future health have been reported in a 
majority of the subjects alive one year after diagnosis, this have earlier been acknowledged 
in other papers as well and this is a concern.  
 
To further increase person centeredness in health-care, the patient’s subjective report of 
their general health, functions and symptoms from treatment and disease by use of HRQoL 
instruments in clinical-decision making, will probably improve symptom management and 
person centeredness.   
 
Recently a genome atlas in oesophageal cancer has reported that both adenocarcinoma and 
squamous cell carcinoma are different cancer types and with further sub classifications 
within each type. In future it would be interesting to investigate whether PRO will differ 
depending on the different subtypes of oesophageal cancer. To further improve HRQoL 
after treatment of oesophageal cancer it is important to investigate whether it exists any 
differences regarding social disparities, economic status, gender differences, age 
differences in Sweden among patients diagnosed with oesophageal cancer. This is should 
be possible with the large number of HRQoL responders within the curative cohort.  
 
Future HRQoL research should also include other important questions regarding known 
side-effects from oesophageal cancer surgery, particularly knowledge of the patients’ 
experiences of both early and late dumping syndrome, a well-known side-effect after 
gastrointestinal surgery. My experience is that dumping may affect the individual’s daily 
life substantially, although how this is specifically manifested and actually influences the 
patient’s daily life is not well investigated. In addition, with more patients becoming 
survivors, other HRQoL measurement is needed, since the instruments used today only 
measure known side-effects from treatment and tumour related symptoms from 
oesophageal cancer in short-term.  
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